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Abstract 
  This thesis explores the barriers to glaucoma care in low-resource environments 
within the context of a non-profit organization (Unite For Sight) and partner clinics 
working in two countries – Ghana and India. The Health Belief and Socio-Ecological 
Models form the theoretical background of glaucoma care delivery. A literature review 
looks at barriers to glaucoma care for programs and patients from structural, economic, 
psychological, and socio-cultural perspectives. Following the literature review, the 
quantitative and qualitative methods are explained – a de-identified patient dataset to 
evaluate glaucoma prevalence at outreaches in Ghana, and field work observations from 
Ghana and India (in the form of blog entries) that elucidate the barriers to glaucoma care.  
Prevalence of glaucoma is found to be very high at Unite For Sight partner clinic 
outreaches near Kumasi, Ghana in July 2013 – 28.17% of patients got the diagnosis. The 
analysis shows glaucoma has an early onset in Ghanaian clinic patients, is asymptomatic 
(23.60% of patients with normal vision have glaucoma), increases nonlinearly with age, 
has no relationship to sex, and differs significantly by outreach location, perhaps due to 
the age distributions at outreaches. The limitations of the data are explored. 
The qualitative data shows that barriers to glaucoma care occur at three levels – 
barriers to understanding prevalence, barriers to diagnosis, and barriers to treatment. Each 
of these occurs via either a structural/economic or psychological/socio-cultural 
mechanism, for both the program and the patient. Barriers include lack of research on 
glaucoma, program structure that does not fully address glaucoma, and complex patient 
barriers to successful glaucoma care. 
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Introduction  
 Approximately 60.5 million people worldwide have glaucoma, and 8.4 million are 
blind from the disease (Ravi 2012). 75% of glaucoma occurs in the developing world 
(Schwab 2007:99). These statistics alone suggests the importance of addressing glaucoma 
prevalence, diagnosis, and treatment in low-resource environments. Furthermore, the 
typically asymptomatic nature of the disease until the late stages, the inability to prevent 
it from occurring, and the irreversibility of vision loss (as opposed to cataract) makes it a 
particularly sinister and therefore crucial disease to address if attempting to reduce the 
prevalence of blindness worldwide. Unfortunately, 50-90% of true glaucoma patients 
remain undiagnosed, and this figure is closer to 90% in low-resource environments 
(Nayak et al 2011). The lack of glaucoma care is partly based on poor understanding of 
glaucoma prevalence and is accompanied by lack of access to diagnosis and treatment.  
These three levels of care (prevalence, diagnosis, and treatment) are influenced by 
four barriers to care: structural, economic, psychological, and socio-cultural. The 
following thesis includes a literature review of these barriers, from a general as well as a 
resource-limited context, particularly Ghanaian and Indian. The goal of this research is to 
further elucidate these barriers, which were observed at Unite For Sight partner clinic 
outreaches in Ghana as well as in Chennai, India. A mixed methods approach is used to 
accomplish this goal. A de-identified (name-free and birthdate-free) patient dataset 
illustrates the geographic distribution of glaucoma at Unite For Sight outreaches in 
Ghana, to document overall prevalence in the Ghanaian clinic patients (but not of Ghana 
in general, because the sample is not random). A month-long series of my blog entries – 
 3 
 
the mechanism for recording field notes – was analyzed thematically for specific 
structural, economic, psychological, and socio-cultural barriers to care seen in Ghana; a 
10-day series of my blog entries from Chennai, India was used to compare the barriers in 
Ghana to the ones in Chennai, India. Ultimately, the research can be used by Unite For 
Sight to improve their work on glaucoma in both countries and can also be used by other 
organizations and individuals working on glaucoma care in low-resource environments.  
Work to improve glaucoma diagnosis and treatment is crucial for patients with the 
condition, as maintaining their vision health allows them to live active and productive 
lives, contributing to the growth of their communities. An ignorance of the barriers to 
glaucoma care will continue to reinforce the vast disparities in access to glaucoma 
diagnosis and treatment around the world (Nayak et al 2011). Such disparities must be 
addressed if we are interested in diagnosing and treating patients with glaucoma in an 
equitable way, regardless of their socioeconomic position and material conditions. 
Glaucoma 
Glaucoma is a chronic progressive disease of the optic nerve associated with 
increased intraocular pressure that causes progressive vision loss. Glaucoma is not 
preventable, although some risk factors predispose an individual to glaucoma. It is 
manageable with a variety of medical and surgical techniques (Schwab 2007). 
Prevalence 
Glaucoma is the second leading cause of blindness in the world after cataracts. It 
accounts for 12% of the world’s blindness (WHO 2013). As previously mentioned, 75% 
of glaucoma occurs in the developing world (Schwab 2007:99). In Ghana, glaucoma is 
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“the most common cause of irreversible blindness” (Ntim-Amponsah et al 2004b). 
Prevalence increases slightly with age in Ghanaian communities – 7.7% for people 30 
years old and under, increasing to 8.5% for people 40 years and older – but is considered 
predominantly a disease of the elderly in most (Western) literature. According to some 
studies in Ghana, prevalence does not seem to differ significantly by gender nor by ethnic 
group in diverse metropolitan areas (Ntim-Amponsah et al 2004b). However, Ntim-
Amponsah (2004b) looked only at locations with ethnically diverse populations 
(attempting to study prevalence by ethnic group), perhaps missing locations that are 
ethnically homogeneous which may have different (or higher) glaucoma prevalence due 
to the heritability of glaucoma. Additionally, there is a rural versus urban distinction in 
the severity of visual field loss due to glaucoma, in that rural patients tend to have more 
severe visual field loss due to lack of access to diagnosis and treatment (Ntim-Amponsah 
2002).  
However, it is important not to extrapolate the prevalence in Ghana to that of 
prevalence in all of Africa or to all “blacks”, as prevalence in parts of rural Northern 
Nigeria, for example, has been reported as low as 1.02% of the population (Murdoch et al 
2001). Prevalence of glaucoma in Africans and people of African descent varies 
significantly – from 8% in a study in Ghana, to 9.6% in a study of a population in St. 
Lucia, to 3.5% in urban South Africa (Budenz et al 2013:655). Comprehensive Ghana-
specific regional studies that look at the factor of age, heritage, socioeconomic class, and 
rural/urban distinction are not present in the literature, suggesting a space for new 
research.  
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In India, the prevalence is somewhat lower compared to Ghana. India is made up 
of various ethnic groups and thus prevalence likewise varies by region. Population-based 
surveys have found the prevalence to be  6.1% in Hyderabad, Andhra Pradesh, 3.2% in 
Madurai, Tamil Nadu, and 3.4% in Calcutta, West Bengal; in Dhaka, Bangladesh, the 
prevalence is 2.4% (Raychaudhuri et al 2005). Thus, prevalence varies from region to 
region in India, and certainly between countries on the Indian Subcontinent/Southeast 
Asia. Rural populations in south India (where Chennai is located) have a prevalence of 
around 1.62%, with 98.5% of the population not being aware of the disease (Vijaya et al 
2005). Urban studies in south India show slightly higher prevalence of 4.32%, perhaps 
explained by the more advanced techniques available in urban areas that more accurately 
diagnose glaucoma (Jacob et al 1998).  A population-based study in Chennai found 
higher rates of glaucoma in patients who have undergone cataract surgery, as glaucoma is 
a potential complication following eye surgery (George et al 2010). Thus, the somewhat 
lower prevalence in India is not to suggest that glaucoma is less important to address in 
this environment, especially as aging populations have access to cataract surgeries from 
which glaucoma can develop. 
Types of glaucoma  
The optic nerve is the part of the eye that becomes damaged in glaucoma, leading 
to glaucomatous loss of vision. The main mechanism for glaucoma is obstruction of the 
trabecular meshwork, where intraocular fluid leaves the anterior (front) chamber of the 
eye, causing increased intraocular pressure (Schwab 2007:99). 
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 There are several types of glaucoma. First, glaucoma can be categorized into 
primary and secondary – occurring on its own or precipitated by another eye condition 
(such as trauma to the eye, diabetes, or eye infection) or by eye surgery (such as cataract 
removal). Primary glaucoma can be further subdivided into primary open-angle and 
primary angle closure glaucoma. Open-angle glaucoma is a disease in which materials in 
the eye such as proteins or pigment deposit in the trabecular meshwork. Angle closure 
glaucoma occurs in smaller, farsighted eyes where the meshwork is obstructed by the iris. 
Open-angle glaucoma tends to be chronic and is “more prevalent and more severe in 
patients of African origin or descent”; angle-closure glaucoma can be both acute and 
chronic and is described by general textbook sources and academic literature as “most 
common in Asian populations, particularly in India and China” (Schwab 2007:101).  
The quantitative aspect of this research will address chronic primary glaucoma (as 
the data distinguishes between chronic versus traumatic/acute), without distinction of 
whether it is open or closed-angle. This is because data available for this research does 
not specify whether a patient’s glaucoma diagnosis is of closed versus open angle, 
although open-angle is presumably the most prevalent type among patients at Unite For 
Sight outreaches in Ghana, given that only about 6.6% of Ghanaian glaucoma patients 
have angle-closure glaucoma (Herndon et al 2002). Similarly, the qualitative aspect of 
this research speaks about glaucoma generally, not specifying closed or open-angle. 
Regardless of whether the glaucoma is open-angle or closed-angle, it is the chronic nature 
of the disease that needs to be addressed when providing long-term eye care in a low-
resource environment.  
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Diagnosis   
Glaucoma can present in many ways, but in the most classic form, intraocular 
pressure is higher than 21 mmHg (with 10-21 mmHg reference range), there is loss of 
visual field (first peripheral vision and, later, central vision), and the optic nerve appears 
excavated (i.e. changes occur in the shape of the optic disc at the back of the eye). A 
family history of glaucoma is highly important, as are risk factors such as “diabetes 
mellitus, African descent, and ocular injury” (Schwab 2007:103). Diagnosis of glaucoma 
can be made using relatively simple tools and techniques: the IOP can be measured using 
a tonometer, finger counting and cross-confrontation visual-field testing can be used to 
check for peripheral visual field loss, and a slit lamp or direct ophthalmoscope can be 
used to assess the changes in the optic nerve.  Such tools are used at Unite For Sight 
outreaches in Ghana, but not in Chennai, India, where glaucoma is diagnosed by the 
ophthalmologist at an eye clinic, not by the optometrist during the outreaches (because 
only ophthalmologists are permitted to make a glaucoma diagnosis in India; see Results 
for more detail). In both Ghana and India, Unite For Sight outreaches are run by 
optometrists; the ophthalmologists practice only in the clinics. 
Treatment 
While loss of vision due to glaucoma is typically irreversible, Schwab (2007:109-
112) summarizes the medical and surgical methods available to manage and prevent 
further vision loss. Medications (typically available as either eye drops or ointments) can 
reduce eye pressure by two mechanisms. One type (including epinephrine, beta-blockers, 
and carbonic anhydrase inhibitors) reduces intraocular pressure by decreasing how much 
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fluid the ciliary body produces. Each of these three drugs has its own drawbacks. For 
example, epinephrine increases heart rate, stings the eye, and requires refrigeration; beta-
blockers slow the heart rate, may exacerbate asthma, and are expensive for long-term use; 
carbonic anhydrase inhibitors cause serious long-term side effects such as kidney stones. 
A second type (including pilocarpine) reduces intraocular pressure by improving aqueous 
outflow through the trabecular meshwork; pilocarpine has uncomfortable side effects 
such as headaches, dim vision, and nausea. Other medications such as alpha agonists and 
prostaglandin analogs have a combination of mechanisms for lowering intraocular 
pressure, but are expensive and may require refrigeration. Thus, medical treatment 
becomes very problematic, especially over the long term with monthly eye drop 
prescription costs, periodic check-ups, side effects, and lack of access to medication for 
various reasons. Access to refrigeration is an additional problem in low-resource 
environments. 
 Surgical management of glaucoma is carried out by filtration surgery, which is 
used to reduce the intraocular pressure permanently, to protect whatever vision is left. 
Filtration surgery has two components or approaches– a trabeculectomy (removing some 
of the blocked trabecular meshwork, creating a small hole or fistula to drain fluid) and 
glaucoma tube surgery (inserting a drainage tube in the anterior chamber to shunt fluid to 
an external reservoir). An iridectomy (creating a small fistula in the iris) can also be 
performed as a treatment for acute angle-closure glaucoma. Trabeculectomy and 
iridectomy can be “performed under local anesthesia using cataract instruments,” but, for 
reasons unclear, “filtration operations frequently fail in darkly pigmented people [as the] 
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fistula closes by scarring and then ceases to function” (Schwab 2007:113). As such, 
“patients who are of African descent may require antifibrotic agents when undergoing 
[first-time] filtration surgery” – i.e. antimetabolite medication becomes necessary to 
maintain the fistula, thereby making the usefulness of a surgical approach limited when 
working with patients in certain low-resource environments (Lee et al 1999:385). 
Additionally, glaucoma tubes for glaucoma tube surgery are expensive, not readily 
available, and can cause significant late complications; glaucoma surgery requires a high 
level of training and high rate of post-surgical follow-up (compared to cataracts). Thus, 
the main method of treatment in low-resource environments is medical rather than 
surgical. 
Unite For Sight and Partner Clinics 
To understand the context of the research, information on Unite For Sight and its 
partner clinics is necessary. Unite For Sight (UFS) is a non-profit organization based in 
the United States, founded in the year 2000 by a Yale University undergraduate, Jennifer 
Staple-Clark. The aim of the organization is to improve eye care access to patients in 
developing countries. The organization began with several years of fundraising via 
growing numbers of university chapters throughout the United States, established from 
2003 onwards. With the funding gained through 25 university chapters, Unite For Sight 
began partnering with already-existing clinics in developing countries – the first one in 
Accra, Ghana in 2004. As fundraising continued, more partnerships were established, 
allowing for greater numbers of patients to be served. Today, such partner clinics – 
established prior to UFS partnership and owned and run by local staff and local 
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ophthalmologists in Ghana, India, and Honduras – have served over 1.6 million patients 
(UFS 2013b). Unite For Sight prides itself on working with local communities and clinics 
and creating sustainable partnerships that are well regarded in the global health 
community. This research is based on volunteering carried out in clinics in Ghana and a 
clinic in Chennai, India. 
Unite For Sight helps the eye clinics treat more patients by subsidizing the cost of 
eye surgery for patients living in poverty, who would otherwise not be able to pay for eye 
surgery. In Ghana, UFS subsidizes cataract and pterygium
1
  removal surgery; in Chennai, 
India, UFS subsidizes cataract surgery. Surgery patients are located during outreaches, 
which will be discussed shortly. In addition to subsidizing eye surgeries, Unite For Sight 
accepts volunteers from the US and other countries year-round to assist the clinics’ staff 
in taking patient histories and doing simple visual acuity screening. Such volunteers also 
fund-raise prior to their volunteer experience abroad ($1800 per trip), and it is this fund-
raising that subsidizes the surgeries. Volunteers also donate and bring abroad 600 eye 
glasses as part of their volunteering. Additionally, a volunteer must observe and sign that 
he or she has observed any surgery that is sponsored by Unite For Sight, to verify that 
every surgery that is sponsored is carried out. This ensures that the funds for sponsored 
eye surgeries are used appropriately.   
In order to find patients who would benefit from eye surgery that Unite For Sight 
would subsidize (in addition to providing eye glasses at a token fee), each eye clinic runs 
outreaches to high-need rural or urban areas, anywhere from 1 hour to 8 hours away from 
                                                          
1 Pterygium is tissue that grows over the surface of the eye, eventually obscuring vision. It occurs in 
people who work in dusty conditions and in the outdoors with high UV exposure. 
 11 
 
the clinic (UFS 2013a). The clinics are the ones who determine if a community is high-
need and the outreaches are based on clinic-established connections with community 
leaders/liaisons who publicize and promote the outreaches. (Of course, this makes the 
data in this study highly biased towards looking at only these outreaches.) On the day of 
the outreach, the clinic staff (composed of at least one optometrist and several clinic 
employees) and foreign volunteers arrive at the outreach village and set up a screening 
process to check for everything from refractive error to the presence of cataracts and 
glaucoma. The community liaisons help facilitate the outreach process. 
The structure and extent of the comprehensiveness of the outreaches varies by 
location and between countries. Since the community liaisons will have publicized the 
outreach, anywhere from 50 to 500 people arrive at the outreach site, and the outreach 
team spends the day screening the patients. For simple conditions such as refractive error 
or eye allergies, glasses and eye drops are sold. Glaucoma eye drops are sold in Ghana, 
but are not sold at Chennai outreaches because the optometrist does not diagnose 
glaucoma during outreaches. While the glasses are donated by volunteers and sold at a 
token fee (to ensure that patients value and use the glasses), medicines such as eye drops 
are sold at a market price.  
From a group of several hundred screened, a dozen people may require eye 
surgery (for cataract and pterygium in Ghana, and cataract in India). Such patients are 
given an appointment slot at the partner eye clinic for a Unite For Sight-subsidized 
surgery several weeks away; the community liaisons coordinate transportation to the 
clinic for the patients coming from the same location (the patients typically pool together 
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money for a shared mode of transportation). While many patients decide to get surgery, 
there are also many who decline for various reasons. Similarly, some patients decline to 
purchase glaucoma or other eye medication or glasses.  Barriers to glaucoma care will be 
presented through the research done in this eye care setting.  
Theoretical Insight  
 Two main theories inform the analysis in this thesis. The Health Belief Model 
looks at individual-level variables that impact health care decision making, and the 
Socio-Ecological Model connects the individual to larger social structures. It is at the 
successful interaction between individual and social structures that glaucoma prevalence 
is best understood, diagnosis emphasized, and treatment carried out. 
Health Belief Model 
 The Health Belief Model is a psychologically-driven theory that predicts an 
individual’s behavior related to health care decisions.  The main assumption of the theory 
is that individuald will evaluate healthcare choices based on how likely they perceive 
themselves to benefit (or prevent harm) by making certain healthcare decisions. The core 
component of the Health Belief Model is the patient’s perception of their condition. 
Patients negotiate a healthcare decision according to four factors: perceived severity of a 
condition, perceived susceptibility to a condition, perceived benefits from obtaining 
diagnosis or treatment, and perceived barriers to obtaining diagnosis and treatment. 
Mansberger et al (2103) applies these constructs of the Health Belief Model to the 
treatment of glaucoma, particularly eye drop adherence (sometimes referred to as 
compliance, although adherence suggests a more amicable and cooperative relationship 
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between the patient and health care provider).  Under the Health Belief Model, a patient 
with glaucoma will adhere to treatment if “he or she places a high value on his or her 
current level of vision and also believes that ocular hypotensive medication will prevent 
further vision loss” (Mansberger et al 2013).   
On the component of perceived severity, patients form an opinion of how serious 
glaucoma and its consequences are; patients must perceive that they could go blind from 
glaucoma in order to seek an eye checkup/diagnosis and to maximize their likelihood of 
adhering to treatment.  
On the component of perceived susceptibility, patients form an opinion of how 
likely they are to develop glaucoma; patients must understand their family history and 
make a decision to seek a diagnosis and treatment based on this history.  
On the component of perceived benefits, patients form an opinion of how helpful 
an eye checkup/diagnosis is and decide if they think eye drops will be effective in 
lowering their chance of going blind from glaucoma; patients must have the perception 
that an eye checkup is a good idea and that eye drops are one of the most effective ways 
of lowering eye pressure and preventing blindness from glaucoma. 
On the component of perceived barriers, patients form an opinion on the difficulty 
and cost of obtaining diagnosis and treatment; patients must value the diagnosis and eye 
drops highly enough to make tradeoffs against other financial, time, and psychological 
demands or constraints (Mansberger et al 2013: Table 1). According to the Health Belief 
Model, it is when all these perceptions are aligned that diagnosis and long-term, 
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successful treatment occurs. Thus, any deviation in these perceptions presents a barrier to 
glaucoma diagnosis and treatment.  
Socio-Ecological Model 
 While the Health Belief Model is patient-centered and primarily psychological in 
nature, the Socio-Ecological Model (SEM) helps us make the connection between the 
patient and the external environment. Certainly, patient perceptions are not formed in a 
vacuum and are influenced by external layers of society. Different formulations of the 
Socio-Ecological Model have identified different layers in the Model. At its most basic, 
the Socio-Ecological Model looks at the relationship of the individual to other 
individuals, the relationship of the individual to the community, and the relationship of 
the individual to society. Other variants of the SEM look at individual-level, 
interpersonal-level, organizational-level, community-level, and policy-level variables and 
how these impact health. The SEM has been applied to everything from violence to 
colorectal cancer prevention (Centers for Disease Control and Prevention 2013). 
 Applying the Socio-Ecological Model to glaucoma, the individual level represents 
many of the facets of the Health Behavior Model. This includes an individual knowing 
about glaucoma and pursuing a diagnosis and treatment, and having access to such 
diagnosis and treatment. The interpersonal level represents patient interactions with eye 
care professionals, who inform the patients about glaucoma, suggest and carry out a 
glaucoma screening, and put the patients on the way to long-term treatment. Other 
interpersonal-level actors include other patients who have or do not have glaucoma, and 
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family members with glaucoma; such actors can influence the patient to seek a diagnosis 
and treatment.  
The organizational level represents larger organizational attempts at addressing 
glaucoma. In a non-profit such as Unite For Sight and its partner clinics, this involves an 
organizational awareness of glaucoma, employing professionals who can diagnose and 
treat glaucoma, distributing and subsidizing glaucoma medication, and emphasizing 
glaucoma diagnosis and treatment as one of its organizational goals. Additionally, 
organizations can be leaders in disseminating knowledge and awareness about glaucoma 
prevalence, to reinforce the importance of diagnosis and treatment. At the community 
level, schools, community groups, media, local leaders, and religious institutions play a 
role in disseminating information about prevalence, importance of diagnosis and 
treatment, so that people can make informed health decisions per the Health Behavior 
Model. Lastly, at the policy level, local and federal/national governments and 
international institutions can provide funding, research emphasis, and policy emphasis via 
national health campaigns, which can provide information about prevalence and 
encourage diagnosis, and provide treatment by creating the appropriate healthcare 
infrastructure. Thus, the Socio-Ecological Model and the Health Behavior Model work 
together, integrating the individual and the external or environmental requirements for 
successful glaucoma diagnosis and treatment. 
Barriers to Glaucoma Care 
It is important to conceptualize what one means by successful glaucoma care, and 
where such barriers to care can occur. This thesis will look at barriers to care as occurring 
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at three distinct levels: 1) a misunderstanding of the prevalence, 2) a lack of diagnosis, 
and 3) a lack of adequate long-term treatment. These three levels interact with four 
categories of barriers – psychological, economic, structural, and socio-cultural, each of 
which is inseparable from the other three – and these barriers are experienced by both the 
patient and the eye health care provider/program. The structural barriers include 
procedural and medical system issues that prevent proper glaucoma prevalence 
assessment as well as lack of proper diagnosis, tracking of patients, and proper disease 
management from the glaucoma care provider position. The economic barriers of 
providing glaucoma care occur from both the patient perspective of purchasing and 
managing medication costs and follow-up visit costs, as well as the provider perspective 
of providing such services. The psychological barriers affect diagnosis, follow-up, and 
eye drop adherence for glaucoma patients, particularly in resource-limited settings. The 
socio-cultural barriers of providing glaucoma care occur at the intersection of patient and 
provider and include language as well as cultural barriers related to perceptions of health, 
disease, and proper treatment. For each of these components, proposed as well as 
successfully and unsuccessfully implemented solutions exist and will be analyzed – thus, 
something that is a barrier in one location may have been addressed in another location. It 
is extremely important to keep in mind that each one of these components rarely occurs 
separately, and it is difficult to divide up barriers as strictly structural, economic, 
psychological, or sociocultural. Thus, each aspect will be analyzed always in relation to 
the three others. 
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Structural Barriers 
The structural barriers to care are predominantly oriented towards the provider, 
which can be conceptualized on both a macro level – of the government or international 
institutions as providers of care as well as research studies on glaucoma – as well as the 
micro level – of individual care providers, particularly non-profit organizations that work 
in low-resource environments. These two halves must be “viewed in the context of a 
health care system” and can include “public, private, civil society as well as emerging 
models of social entrepreneurship and public private partnership” (Damji 2013:3). 
Structural barriers exist at every level and have effects on the understanding of 
prevalence, proper diagnosis, and proper treatment. 
One barrier to understanding glaucoma prevalence and successful diagnosis and 
treatment is that many international organizations geared towards improving eye care are 
not focused on glaucoma. For example, international efforts such as VISION 2020 focus 
on five conditions: cataract, trachoma, onchocerciasis (river blindness), eye conditions in 
children, and refractive error and low vision. Diabetic retinopathy is to be added to the 
priority list because of the increase in diabetes in developing countries, whereas 
glaucoma ambiguously “remains on the agenda due to difficulties in its early diagnosis 
and frequent necessity of life long treatment” (WHO 2004:1). Thus, glaucoma seems to 
be secondary to other, more easily managed and curable eye conditions.  
In terms of understanding prevalence, the large emphasis on infectious diseases in 
developing countries overshadows chronic, non-communicable conditions such as 
glaucoma (Bowen 2011). A meta-analysis carried out by Kyari et al (2013) found a total 
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of nine population-based studies (PBS) of glaucoma in Sub-Saharan Africa, and “three 
were classified as good, one was satisfactory, and five had incomplete reporting” (Kyari 
et al 2013). Kyari et al (2013) also found four glaucoma prevalence studies in African-
derived populations living outside of Africa, and fifty-five publications looking at 
blindness and visual impairment in Sub-Saharan Africa, with glaucoma not mentioned or 
not clearly defined. Thus, Kyari et al (2013) concluded that “there are few PBS 
(population-based studies) data that provide estimates of any/all types of glaucoma in 
Sub-Saharan Africa, and only four provide reliable estimates.”  
Additionally, an understanding of prevalence on the part of the patient is 
necessary before diagnosis can be pursued. A very low percentage of patients in 
developing countries are aware of what glaucoma is, not to mention its risk factors and 
heritability. A study at ophthalmic outreaches in Southwestern Ethiopia, for example, 
found that only 2.4% of outreach patients knew about glaucoma (Tenkir et al 2010). 
Similar results are found in Ghana, and will be discussed later. Such low results illustrate 
a need for public health campaigns and education in schools and other locations geared 
towards glaucoma prevalence (including an awareness of risk factors and heritability), 
diagnosis, and treatment. 
Even if prevalence is understood, there are structural barriers at the level of 
diagnosis and treatment, suggestions for which have most recently been elucidated in The 
International Centre for Eye Health’s (ICEH’s) Community Eye Health Journal Vol. 25 
Issues 79 and 80, 2012. One barrier is the simple lack of healthcare professionals who 
can diagnose glaucoma, something that can be ameliorated with “people working in 
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primary health care [who] have a major role to play in the counseling of patients and their 
relatives who are also at risk” and “mid-level personnel with good training and 
supervision [who] can help by taking regular measurement, capturing and transferring 
information and images, and making timely referral of patients according to agreed 
clinical guidelines and protocols” (ICEH 2012:42). Such an approach can circumvent the 
problem of the limited number of trained eye care professionals, and this can be 
accomplished with the aid of community liaisons and emphasizing treatment provided by 
optometrists rather than ophthalmologists.  
Once diagnosis is achieved, structural issues at the level of treatment arise. Since 
glaucoma requires long-term treatment with regular follow-ups, it is necessary to improve 
patient experiences and the level of care during follow-up visits (not to mention reduce 
geographic/transportation barriers to follow-up visits): “treat patients on a strictly first-
come, first-serve basis… improve record keeping and filing systems… and reduce 
waiting times” (ICEH 2012:45).  
To summarize the structural barriers for glaucoma care: 
Glaucoma care needs to be given high priority in Vision 2020 programs in 
Africa. Many questions remain unanswered and there is a need for further 
research in glaucoma in SSA [Sub-Saharan Africa] in all aspects 
especially epidemiology and clinical care and outcomes involving 
randomized controlled trials. Genetic and genome-wide association studies 
may aid identification of high-risk groups. Social sciences and qualitative 
studies, health economics and health systems research will also enhance 
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public health approaches for the prevention of blindness due to glaucoma 
(Kyari et al 2013). 
Structural Barriers in Ghana and India 
Barriers to understanding prevalence occur because there is limited research 
carried out on the issue of glaucoma prevalence. Unfortunately, the single Ghana-specific 
study identified by Kyari, et al (2013) was classified as “incomplete”, while only four 
carried out in the entirety of Sub-Saharan Africa were considered good or satisfactory. 
Clearly, the lack of research geared towards glaucoma prevalence, particularly 
geographic distribution (as prevalence ranges from 1.02% in Nigeria to 8.5% in Ghana), 
is one of the large structural barriers that then make diagnosis and treatment difficult 
(Kyari et al 2013). Not many more population-based studies have been carried out in 
India – George et al (2007) identified five such studies in several rural and urban 
locations around India, not enough to represent the 11.9 million people who have 
glaucoma in the large and ethnically diverse country (George et al 2007). 
In terms of raising awareness on a large scale, the First African Glaucoma 
Summit was held in 2010 in Ghana, as the World Glaucoma Association “has decided to 
make Glaucoma in Africa the focus of its international education effort, and the meeting 
in Ghana is a first step in that direction” (WGA 2013). The Ghanaian government, via the 
Ghana Health Service (GHS), has likewise “over the years initiated various programs 
aimed at improving the eye care system in the country. The month of January has, 
therefore, been set aside by the World Glaucoma Association to promote education on the 
disease” (Al-Hassan 2013). In India, World Glaucoma Day was most recently 
commemorated by the Vidarbha Opthalmic Society and several articles have been 
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published in the Times of India (Gwalani 2014).  This suggests some attempts by 
international organizations, the Ghanaian government, and Indian ophthalmic societies 
and news outlets to spread awareness about glaucoma in the population. 
In terms of the patient’s awareness of the prevalence of glaucoma, a study in 
Ghana found that 3.5% of 1775 community members were aware of glaucoma, 0.8% 
understood it, and 1% knew that it could be hereditary (Ntim-Amponsah et al 2004a). In 
India, a study found that 98.5% of rural patients in one study were unaware of glaucoma 
(Vijaya et al 2005). Thus, patient education is equally important in India and in Ghana. 
Without knowledge that glaucoma is a threat to eyesight, there is a limit to how well care 
can be provided. Glaucoma may then often only be diagnosed once the patient comes to 
an eye care professional for a pair of reading glasses or other eye problems not related to 
glaucoma, and who might already be experiencing advanced visual field loss. In Ghana, 
96% of rural and 76% of urban patients diagnosed with glaucoma already had an 
advanced case of the condition (Bowen 2011:17). Structural barriers in access to 
education as well as access to eye care create such discrepancies in awareness and 
outcomes. 
Another powerful structural limitation is the number of eye care professionals 
able to treat glaucoma. In Ghana, there are two ophthalmologists for every million people 
and, in India, there are nine ophthalmologists for every million people; this can be 
compared to eighty-one for every million people in the United States (ICO 2013). 
Additionally, ophthalmologists are typically located in urban areas, with 70% of Indian 
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ophthalmologists practicing in urban areas, although the vast majority of the population 
lives in rural areas (De Souza et al 2012). 
Looking at optometrists, there are “about 50 optometrists for a population of 
nearly 20 million” in Ghana, which translates to approximately 0.25 per 100,000 
(Thompson 2002). This can be compared to 7.83 optometrists per 100,000 in the US (The 
New York Center for Health Workforce Studies 2006:132). In India, optometry training 
varies, but the more prevalent two-year courses in optometry do not allow the optometrist 
license to diagnose glaucoma and provide comprehensive care; four-year education 
programs are just becoming established and these allow for more comprehensive 
treatment, including glaucoma diagnosis (De Souza et al 2012). This profound shortage 
of eye care professionals who can diagnose glaucoma in Ghana and India makes 
structural inadequacies of the system quite acute. Patients have little face-to-face time 
with eye care professionals, who have little time available to educate patients. Other 
routes to educating, diagnosing, and treating patients (such as the use of rurally-located 
community health workers) are being tried by organizations such as the Carter 
Foundation, which is “training a corps of healthcare workers throughout seven 
universities in Ethiopia, so that even people in the most remote areas will have access to 
treatment” of onchocerciasis (river blindness) (Poole 2007). Similar efforts can be 
attempted for glaucoma. 
Economic Barriers 
 Unlike structural barriers, which tend to be provider-oriented, the economic 
barriers to glaucoma care can be seen from the perspective of the patient as well as the 
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perspective of the provider/program, at the levels of an understanding of prevalence, 
access to diagnosis, and access to treatment. In this section, since the research was done 
on a small scale and in the context of the non-profit sector, the provider is defined more 
narrowly as non-profit organization that is pursuing healthcare benefits for the 
community, while also keeping an eye on costs. 
 Obtaining a glaucoma diagnosis is crucial – as previously mentioned, 50% of 
patients in any community remain undiagnosed, while 90% remain undiagnosed in 
limited-resource environments (the particular study taking place in India) (Nayak et al 
2011). While lack of diagnosis can occur because of psychological, socio-cultural, and 
structural reasons, the literature also unanimously agrees that: “some patients do not have 
access to professional eye care because of insufficient financial resources or no means of 
transportation” (Nayak et al 2011).  
 For community-based eye care organizations, “although the office-based 
identification of glaucoma can permit the early detection and treatment of the disease and 
can be cost effective, [glaucoma screening] has yet to prove a cost-effective strategy in a 
community setting” (Picciani et al 2011).  When evaluating usefulness of glaucoma 
screenings, it is useful to look at the examination cost per case detected. The Nettie 
Taylor Project in Philadelphia, for example, used low-paid and volunteer staff and low-
cost equipment to test for glaucoma in 2000 patients. Twenty 2-hour sessions led to a 
diagnosis rate of 10% with a cost of $140 per diagnosis, and using more expensive 
technology would have increased the cost to $290 to $465 per diagnosis.  To reduce the 
costs per patient, “more targeted screenings within populations [who are] both at high 
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risk for glaucoma and likely to benefit from earlier treatment might be cost-effective.” 
The Nettie Project, therefore, focused on elderly African Americans, which “helped 
increase the screening yield” but was also plagued with a very low follow-up rate 
(Picciani et al 2011). Thus, glaucoma screening is a cost-effective tool if targeted 
specifically to certain high-risk populations who will have access to continued treatment. 
Such targeting, of course, rests on an understanding of the prevalence, which is often 
poorly understood due to economic and structural barriers that make such research 
difficult (Picciani et al 2011).  
Moving on to treatment, in a yearlong study carried out in the Netherlands 
healthcare system, costs for glaucoma treatment varied for several reasons. First, 
depending on the severity of the diagnosis, a diagnosis of ocular hypertension without 
other symptoms was less costly than a complex diagnosis of glaucoma. Patients with 
ocular hypertension had an average of 2.43 visits to the ophthalmologist per year, 
whereas those with advanced glaucoma had an average of 3.74 visits per year, and the 
mean cost per patient was $280 and $559, respectively. Patients with no changes in 
medication therapy paid a mean of $347 for their care, whereas those with more than 
three adjustments paid $1765 for their care.  Following the diagnosis, the major 
determinants of these costs were thus the number of outpatient visits to the 
ophthalmologist, medication costs, and the type of hospital frequented (general or 
academic, which was more expensive) (Oostenbrink et al 2001). A similar study in the 
US found that “the average direct cost of glaucoma treatment [also partially covered by 
Medicare] ranges from $623 per year for patients with early-stage glaucoma to $2511per 
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year for end-stage patients” and that “medication costs composed the largest proportion 
of total direct costs for all stages of disease (range 24%-61%), even while controlling for 
adherence rates” (Lee et al 2006). Thus, physician and medication costs are the major 
economic drivers of barriers to glaucoma treatment, and insurance is a necessity when 
paying for glaucoma care. Additionally, glaucoma that is being treated at an early stage 
has much lower costs associated with it, showing the importance of early diagnosis from 
an economic perspective. 
Minimizing cost of providing care is of utmost importance to a non-profit 
provider. Screening should be “for eye disease in general, not just glaucoma” and “not 
only should populations be carefully targeted based on disease prevalence, but [also] on 
the likelihood that subsequent care will be delivered” (Picciani et al 2011). To manage 
equipment costs, the “skills of someone trained to evaluate the optic nerve to make a 
diagnosis, especially in cases of early disease” should be used, rather than more 
expensive and highly specific equipment and tests that are not useful for diagnosing other 
eye diseases (Picciani et al 2011). Thus, organizations should seek to be comprehensive, 
maximize the use of simple technology, and provide diagnosis early-on to those likely to 
get follow-up treatment to minimize the economic costs of running their programs. 
Economic Barriers in Ghana and India 
 The economic barriers to care are much more pronounced in low-resource 
environments, and barriers occur for the patient as well as for the provider at every level 
– of understanding prevalence, of getting a diagnosis, and of obtaining treatment. The 
very lack of studies on prevalence across Ghana and India suggests a variety of barriers 
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to understanding glaucoma, and the economic barriers to such wide-scale research are 
certainly present. 
 Patients in low-resource environments have limited access to glaucoma diagnosis 
because of patient economic barriers to obtaining a comprehensive eye screening, 
including barriers such as transportation costs, screening costs, and opportunity costs, as 
well as a lack of trained eye care professionals. Thomas (2012) concludes that it is best to 
approach diagnosis in developing countries on a case-detection basis, which screens any 
patient presenting at an eye clinic for an eye exam for glaucoma. Thomas (2012) opposes 
population-based screening as a feasible way to diagnose in low-resource environments, 
as “developing countries do not have the requisite infrastructure to categorize and follow 
up test positives on various screening tests, let alone treat the true positives and certainly 
not enough to repeat the process on a regular basis” (Thomas 2012).  However, even case 
detection is difficult in a resource limited setting because of the previously mentioned 
“excessive workload” experienced by the few eye care professionals and “the cost of slit 
lamps, applanation tonometers, and diagnostic lenses” (Thomas 2012). Thus, the 
economic barriers to diagnosis for both the patient and the provider are severe in 
resource-limited environments. 
 In terms of economic barriers to treatment from the perspective of the patient, not 
only are medicines not readily available, but they are also expensive relative to the 
income of the patients –  “even generic beta blockers and pilocarpine may cost more per 
day than basic necessities such as food” (Egbert 2002). Patients in a British study were 
“untreated for short periods, having run-out of drops, failing to re-order drops or having 
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experienced problems obtaining new drops before current bottle expiry” and also 
experienced issues of “keeping drops cool [i.e. refrigerated]”; prescription costs were a 
particular issue (Lacey et al 2009:929). Certainly, such limitations occur in Ghana, as the 
per capita annual income is $1550 in current US dollars, so “patients prescribed 
medications will use them only until the more basic demands of daily living re-assert 
themselves” (World Bank 2012; Thomas 2012). In addition, in Ghana, geographic 
barriers to care (in terms of travel time and difficulty) as well as the costs associated with 
care with the few eye care professionals creates the conditions for an “extremely poor 
rate of follow-up after treatment (19% at six months)” (Verrey et al 1990). To ameliorate 
the financial burden of health care, a National Health Insurance Scheme (NHIS) was 
established in 2005 and covers eye care in Ghana (including subsidizing several 
glaucoma medications); the yearly premium ranges from 20-25 Ghanaian cedis (about 
10-12 USD), but only a maximum of 18% of the population has actively enrolled in the 
program in any given year. The main reason for not joining the scheme (for 77% of 
individuals surveyed) was the inability to pay the NHIS premium, although all tax-paying 
Ghanaians fund the NHIS system through a 2.5% insurance levy added to the VAT 
(Oxfam International 2011:26). Thus, gaining financial help to pay for glaucoma 
treatment is difficult, even with an existing national health insurance program. 
 In India, 69% of ophthalmologists work in the private and NGO sector, while 
31% work in the government sector (Murthy et al 2004). Thus, while government-run eye 
facilities exist, the majority are in the private sector, which is highly fragmented, 
concentrated in urban areas, and costly. A study in rural south India showed that 78.2% 
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of patients reported a lack of funds and 70% reported a lack of time to go to the eye 
doctor; interestingly, 34.1% of patients diagnosed with glaucoma had reported going to a 
hospital for eye care in the past, and 15.9% diagnosed with glaucoma had even visited an 
eye doctor before (Robin et al 2004). Thus, while eye care is available throughout various 
government hospitals all across India, the quality and cost of such care seem to be 
barriers to getting a glaucoma diagnosis and treatment. In a similar study in Tamil Nadu, 
28% of rural patients self-reported taking an hour or more to get to a pharmacy and 
younger patients had more problems paying for their medication, with 21.8% of all 
patients self-reporting financial difficulty. Such economic and structural barriers 
contribute to poor diagnosis and low adherence rates to glaucoma treatment (Sleath et al 
2009).  
Psychological Barriers 
 Psychological barriers occur primarily from the perspective of the patient rather 
than the provider. There are psychological barriers to care at the level of understanding 
prevalence, seeking diagnosis, and maintaining treatment. The Health Belief Model 
serves as a good illustrator of this issue, as it suggests that people must first perceive a 
disease to be important and relevant to them in order to seek diagnosis and then treatment 
(Ogden 2007:23-24). Without proper education and lack of an understanding of 
prevalence and the heritability of the disease, glaucoma diagnosis and treatment does not 
occur.  
There is an age distinction in the psychological perceptions of prevalence and 
susceptibility to glaucoma. In a qualitative study carried out by Lacey et al (2009) in the 
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NHS system of Great Britain, glaucoma patients who tended to be younger (classified in 
the study as under 60 years of age, as Western literature mistakenly yet universally 
considers glaucoma to be an old-age disease) “discussed concern about life-long 
treatment and a feeling of isolation in clinics when surrounded by older patients” and 
often felt “treated differently by staff” (Lacey et al 2009:930). Such psychological 
barriers certainly affect how younger people perceive prevalence and seek diagnosis and 
treatment for their glaucoma. The misunderstanding of the prevalence is also a structural 
issue, however, that relates to a lack of education and a lack of research emphasis on a 
particular issue.  
Once a patient is diagnosed, the key way to prevent vision loss from glaucoma is 
by adhering to medications, particularly eye drops, which prevent intraocular pressure 
from increasing. Psychological barriers strongly relate to eye drop adherence. In Lacey et 
al (2009), patients elucidated some of the barriers they felt towards success of their 
glaucoma care. Patients lamented a lack of down-to-earth, face-to-face education (as 
opposed to using leaflets), suggested that “doctors emphasize the consequences of poor 
adherence, drop application techniques, and advice about application schedules,” and 
hoped that more education would occur throughout follow-up visits (Lacey et al 
2009:927). Thus, lack of education can be seen as a psychological barrier to proper 
adherence. 
Eye drop technique was a particular source of concern and uncertainty for 
patients, who either tended to become comfortable with eye drops over time, or tended to 
never become accustomed to them. Patients suggested that better eye drop administration 
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education is absolutely crucial, as most tended to rely on typically conflicting information 
provided on the eye drop packaging, the Internet, and other sources. Many would have 
liked “their practitioner to check their current technique” (Lacey et al 2009:929). Of 
course, this factor intersects with the structure of the medical system, and the amount of 
time medical professionals have available for each patient, as well as the general 
education level of the population regarding eye care. 
 Another psychological factor is a lack of faith in eye drop efficacy. Patients 
frequently had negative feelings about eye drops’ effectiveness and also disliked the 
negative side effects.  However, some patients did continue to apply eye drops, despite 
the unpleasant side effects, because they already had symptomatic vision loss. Some 
patients “desired more regular feedback about drop efficacy [such as progression of 
disease during follow-ups],” which they felt would provide them with “greater faith for 
adherence” (Lacey et al 2009:929).  
 Another simple yet very crucial component of treatment elucidated by Lacey et al 
(2009) was forgetfulness. Twenty-two out of twenty-four patients admitted to forgetting 
their eye drops at some point, and typically consisted of either frequent/occasional or rare 
forgetters, who would not be concerned or would become very concerned about missing 
their dosage, respectively. Most used some kind of schedule to apply their drops, and 
there was an increase in forgetfulness as the eye drop schedule became complicated.  
Psychological Barriers in Ghana and India 
In Ghana, the age distribution of glaucoma is unique in that glaucoma has a much 
earlier onset; this early onset is seen at outreaches and is documented by various studies 
(Kyari et al 2013). Problematically, the expectation that glaucoma is an old-age disease is 
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not true in Ghana. In addition to a lack of awareness of prevalence, the age factor poses a 
psychological barrier of perception of susceptibility towards disease, as explained by the 
Health Belief Model. About 6% of the 30-34 age category has glaucoma, and this steadily 
increases to 7.3% in the 50-54 age category, and is as high as 27.1% in the 75-79 age 
category (Ntim-Amponsah et al 2004b:Table 2). This distribution suggests that young 
people do get glaucoma, and thus have to overcome the psychological barriers of getting 
such a (typically asymptomatic and thought to be an old-age) diagnosis early in life. 
When looking at psychological factors in relation to treatment, the problem posed 
by patients in Lacey et al (2009) on the need for more face-to-face time with physicians 
intersects with the structure of the medical system. Unfortunately, the amount of time 
medical professionals have available for each patient is extraordinarily limited in low-
resource environments. As discussed previously in the text, there is a profound shortage 
of eye care professionals in Ghana and India, which makes the face-to-face time problem 
extremely acute and education ability of such eye care professionals extraordinarily 
limited, exacerbating the psychological barriers to care. In India, seemingly simple issues 
such as difficulty opening or squeezing the bottle, and not knowing how to apply eye 
drops, led to increased non-adherence among younger glaucoma patients (Sleath et al 
2009). 
The issue of faith in eye drops is particularly acute in low-resource environments, 
where efficacy may be related to an expectation of improvement in vision (when no such 
improvement is possible with glaucoma) due to a lack of education about glaucoma. 
Glaucoma patients at outreaches interact with cataract patients who become cured of their 
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cataracts; lack of such a cure for glaucoma may cause a loss of faith in eye drops. Patients 
may additionally favor glasses over eye drops, since glasses are perceived to “fix” vision. 
The follow-ups that would re-emphasize adherence to medication do not occur because of 
economic, structural, and socio-cultural barriers. Also, the belief that eye drops and other 
treatments are unnecessary for asymptomatic conditions is highly prevalent in low-
resource conditions. Bowen (2011:18) studied this issue in Ghana and found that “while 
talking to glaucoma patients, more than half expressed feeling no need to seek care from 
an eye doctor until they noticed a problem.” This psychological barrier intersects with 
socio-cultural beliefs about disease, but such beliefs are quickly changed when “after 
being diagnosed and receiving glaucoma treatment, patients then saw the value of 
preventive ophthalmologic care.” One patient who is a pastor “invites health 
professionals to speak to his congregation about basic healthcare and the need for certain 
kinds of preventive care” (Bowen 2011:18). 
While forgetfulness seems to be a universal, patients with lower levels of 
education (partially stemming from little face-time with the eye care professional) may 
underestimate the importance of using eye drops and may thereby have a higher tendency 
to forget. Also, patients who are treated for other conditions (such as allergies or 
pterygium) in addition to glaucoma may find treatment schedules unmanageable and may 
forget various doses of various medications. Additionally, patients who are not educated 
about the relative importance of their glaucoma diagnosis (versus their allergy diagnosis, 
for example) may treat all the conditions as equal and may forget glaucoma drops at the 
same rate as other drops. 
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Socio-Cultural Barriers 
 Socio-cultural barriers occur in relation to patients and providers, often at the 
intersection of the two. There are countless socio-cultural barriers that can be identified, 
and only a few will be mentioned here.  
 Morris, et al (2009) carried out a qualitative study that examined the social 
barriers to health care experienced by refugees resettled to San Diego from countries such 
as Somalia, Russia, Iraq, and Afghanistan. Apart from the economic and structural 
barriers to care (such as transportation and healthcare costs), language and 
communications barriers were strongly present. “Language barriers exist not only during 
interactions between doctors and patients but at every level of the health care system, 
from making an appointment to filling a prescription… [and would] lead to refugees 
either utilizing health care services only when they are very sick, or not at all” (Morris et 
al 2009:533). Such language barriers are certainly possible in resource-limited settings 
where many languages are spoken and the languages spoken by the (few) eye care 
professionals differ from that of the patient. When using interpretation services to bypass 
the issue of language, many “health care providers perceived problems with relying on 
family members, including misinterpretation and confidentiality issues” (Morris et al 
2009:534). 
 Another component of the study found that “culture directly affected refugees’ 
concept of prevention services, independence, expectations of care and stigma around 
health care – all of which influenced their health care choices” (Morris et al 2009:535).  
Patients who were refugees were “not fully accustomed to the idea of preventive care” 
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and they had “expectations of western medical care [that included] specific behaviors of 
doctors, curing chronic diseases instead of managing them, and fast care by clinics” 
(Morris et al 2009:535). Gender came in to play, as women from some refugee groups 
felt uncomfortable with health care providers of the opposite sex. Patients in the Lacey et 
al (2009) study encountered socio-cultural barriers to adhering to eye drop regiments 
because of the “difficulties in finding a convenient location (often due to 
embarrassment),” suggesting a certain discomfort of applying eye drops in social 
situations and the stigma of having an illness. Some health care providers also spoke of 
“refugees relying on homeopathic treatments and spiritual healers [which] refugee 
participants did not view as a barrier to accessing medical services here in the US. 
Instead, refugee participants noted that they use some cultural remedies but do not view it 
as a replacement to western care” (Morris, et al 2009:525).  
Socio-Cultural Barriers in Ghana and India 
 While Ghana’s official language is English, there are also nine local languages 
that Ghanaian students can study in school and which are used in daily life, and the most 
widely spoken local languages are Twi, Ga, Dagomba, Akan, and Ewe (Ghana Embassy 
2013). Similarly, while English is an official language in India, patients from each state 
speak several languages; patients in Tamil Nadu, for example, speak almost exclusively 
only in Tamil rather than Hindi. In short, various parts of the each country speak different 
languages, creating a language barrier if the patient is one part of the country and the 
provider is from another; however this barrier may be overstated, since most locations 
were frequented by patients from roughly the same area and language background. 
Additionally, the ability to speak English (which providers in Ghana and India speak 
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almost universally) varies significantly with education levels, so that patients who are 
most in need of care may encounter the greatest language barrier. 
The socio-cultural barrier related to preventive care is also present in Ghana and 
was mentioned in a previous section on psychological issues, as “more than half of 
glaucoma patients expressed feeling no need to seek care from an eye doctor until they 
noticed a problem” (Bowen 2011:18). Expectations of medical care in resource-limited 
environments is not particularly high, as patients in a study in nearby Togo found that 
“56.1% [of patients] were not confident in the local doctors for the treatment of 
glaucoma,” and this serves as a worrying barrier to obtaining care (Balo et al 2004).  
 On the issue of gender, a study by Gyasi et al (2010) found that “despite the 
higher preponderance of male patients with POAG [primary open-angle glaucoma], the 
females were more than twice as likely to become blind from the disease. These findings 
reflect the socio-cultural aspects of male dominance in a many societies where men 
control the family wealth and are more likely to have the upper hand in assessing [the 
value of] ‘pay-for-health care’ services.” Thus, while males tend to have glaucoma at a 
slightly higher rate than females, female blindness is more prevalent from glaucoma. This 
observation is an example of a socio-cultural attitude towards women that reduces the 
access to glaucoma care that women receive, thereby limiting their chance at maintaining 
sight.  
 Similar to the situation of refugees in San Diego, many Ghanaians access 
traditional healers for their healthcare needs. Unlike optometrists and ophthalmologists, 
which are in short supply, there are traditional healers in nearly every community who 
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“often know their patients personally, and have cultural history and societal structure on 
their side.” While there are instances where examples of traditional healing method can 
be harmful, many medicines used today were previously used in traditional medicine. 
The main ingredients in key glaucoma medications, for example, come from natural 
sources: taxol from yew bark, and pilocarpine from jaborandi (Pilocarpus microphyllus) 
(Zelefsky and Ritch 2010:657). Thus, “in the absence of clinical trials it devolves upon us 
to make the best possible guess as to what might or might not be effective in glaucoma” 
(Zelefsky and Ritch 2010:657). Also, Ghanaian patients tend to seek care from both 
western and traditional providers “using whichever method is most accessible or 
promises the best likelihood of healing in that situation” (Klip 2010:5). However, 
sometimes using traditional healers can “cause a delay in patients seeking and receiving 
the correct medical treatment,” leading to “frustration for the health worker, grief for the 
family, and irreversible blindness for the patient” (Abdull 2012:44). Thus, a solution to 
the conflict between traditional and western medicine should be sought, as this creates a 
socio-cultural barrier to glaucoma care. 
Note about Barriers 
The aforementioned literature review of barriers to care at the levels of 
misunderstanding prevalence, missing diagnosis, and poor treatment intersect with 
psychological, economic, structural, and socio-economic factors. It is important to note 
that none of these barriers occur without some input from the others. Also, the specific 
barriers mentioned in this proposal are limited – there are others documented in the 
literature which have not been fully addressed in this thesis. 
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Methods 
 Quantitative Methodology 
 
The research for this thesis was carried out with a mixed methods approach. The 
quantitative aspect of the research involved the use of a de-identified (name-free and 
birthdate-free) patient dataset provided by the optometrist running the partner eye clinic 
outreaches in Kumasi from July 2013, which included information on outreach location, 
age, gender, symptoms, VAR/VAL (visual acuity), diagnosis, and treatment for 969 
patients in Ghana. According to guidelines provided by Lehigh IRB, IRB approval for the 
quantitative data was not required because there was no identifying information and the 
data was collected before the proposed research project was initiated. The data came from 
14 rural outreaches around Kumasi, Ghana, with approximately 69 patients per outreach 
(with a wide range of 21 to 142 per outreach, depending on patient recruitment). The data 
was thus not a random sample, but was rather dependent on the patients that showed up 
to the outreach; it will thus be referred to as the patient population. The patient population 
was self-selecting and potentially highly biased. Thus, prevalence in the patient 
population is not to indicate prevalence in Ghana in general, or even at other outreaches 
or other times of the year. These limitations must always be kept in mind, as the analysis 
was carried out with the highly imperfect data that was collected before the research was 
initiated.  
The data was cleaned, fixing a variety of human data input errors, as well as some 
inconsistencies in symptom description, diagnosis, and specificity of VAR/VAL. Human 
error could never be fully ameliorated, if volunteers entered data incorrectly in a way that 
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cleaning could not fix. It was not possible to ensure that all inconsistencies were 
removed. The maximally-cleaned data was then loaded into and analyzed using STATA 
12. The patient population was first described according to age distribution, distribution 
of patients across villages/locations, sex distribution, combined age/sex distribution, and 
visual acuity of the patient population (See Tables 1-4).The patient population was also 
described according to the prevalence of the various diagnoses (See Table 5).  Glaucoma 
was next focused on specifically, looking at glaucoma prevalence according to various 
age categories using chi-square analysis as well as the mean age of glaucoma patients 
versus non-glaucoma patients using t-test (See Table 6). The likelihood of having 
glaucoma by age was likewise looked at using logistic regression. Glaucoma was 
additionally described according to village/outreach location (See Table 7), and the age 
distribution of each village was compared to the glaucoma prevalence (See Table 8). 
Lastly, glaucoma prevalence at each visual acuity level was analyzed (See Table 9). An 
initial foray into mapping the villages/outreach locations showed that half of the villages 
could not be identified on a map, while the other half showed no pattern in glaucoma 
distribution geographically. As such, GIS mapping was not pursued as originally planned. 
Note that data only on Ghana, in the Kumasi area, was used in the quantitative analysis; 
data on the Chennai, India outreaches was not available and not used.  
Qualitative Methodology 
 
The qualitative aspect of the thesis involved the use of data gathered in Ghana and 
India. The Ghanaian data was obtained during researcher participant observation at Unite 
For Sight daily outreaches run by three clinics – one in Kumasi and two in Accra, Ghana 
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– from July 20th to August 20th, 2013. The Indian data was obtained during researcher 
participant observation at a clinic in Chennai, India during outreaches from January 7
th
 to 
January 15
th
, 2014. The data consisted of forty daily blog entries (thirty three from 
Ghana, seven from India), each approximately one single-spaced page in length. The 
entries were based on observational experiences during twenty-two outreaches to twenty-
two different locations as well as information learned from conversations with clinic 
employees, other volunteers, and community members (all of whom remain anonymous 
in the research) in Ghana and India. The use of the blog entries from Ghana and India as 
a source of data was approved by Lehigh University IRB on November 7
th
, 2013 and 
December 11
th
, 2013, respectively. The approval timeline is unusual because the 
Ghanaian blogs were written prior to the initiation of the research project, whereas the 
Indian blogs were written after the project was initiated, in order to add a comparative 
perspective to the research. 
Three levels of barriers were conceptualized as preventing successful glaucoma 
care: barriers to understanding prevalence, barriers to diagnosis, and barriers to treatment. 
Each piece of information fits under at least one of these levels and each was additionally 
coded as structural, economic, psychological, and/or socio-cultural. Additionally, each 
barrier was coded as either program-level or patient-level and was specific to either 
Ghana or India.  Grounded theory was used to allow these codes to emerge, while also 
relating the themes to existing literature. Microsoft Word software was used instead of 
the initially planned ATLAS.ti, because ATLAS.ti software was unavailable on my 
Apple computer. Thus, codes were applied using comment boxes in Word, and pertinent 
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data was then extracted from the Word documents, organizing the data according to 
themes in new theme-specific Word documents. The write-ups followed from the data in 
each theme-specific Word document.  
In the end, the structural and economic themes were merged into one, as it was 
difficult to discern if a barrier was structural or if it was actually caused by an economic 
issue. Similarly, the themes of psychological and socio-cultural barriers were merged into 
one, because it was difficult to know whether a barrier to care was psychological or 
socio-cultural in nature (particularly from a vantage point of a foreigner doing research in 
Ghana and India). Intersecting with these structural/economic and psychological/socio-
cultural themes, the barriers were identified as pertaining more to the program or more to 
the patient. Thus, for each of the three levels of care (understanding prevalence, 
diagnosis, and treatment), the qualitative results are organized as follows: 
structural/economic barriers (program-side or patient-side) and psychological/socio-
economic barriers (program-side or patient-side) (see Fig. 3 for a visual summary). Some 
sections are indeed split into two (i.e. separate section for structural and economic) 
because of a large amount of data that could be separated out; some sub-sections are 
missing because no data was observed for that section. Intersecting with the 
structural/economic and psychological/socio-cultural at the program-level or patient-
level, the barriers are also compared in terms of location – Ghana and India – as some 
barriers are being ameliorated in one location, and not in another. As such, reduction in 
barriers is another code used throughout the results to illustrate the different progress 
towards reducing barriers to glaucoma care. 
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Results 
 The results of this thesis are presented in two sections – quantitative and 
qualitative. The quantitative analysis is summarized in Tables 1-9, whereas the 
qualitative framework and results are seen in Figures 3 and 4. The quantitative analysis 
does the work of better understanding glaucoma prevalence at Unite For Sight partner 
clinic outreaches around Kumasi, Ghana. The qualitative analysis is broader, reporting on 
the barriers of misunderstanding prevalence, barriers against obtaining a glaucoma 
diagnosis, and barriers to glaucoma treatment at Unite For Sight partner clinic outreaches 
in both Ghana and India. Thus, while the quantitative part of the research informs 
glaucoma prevalence in the patient population, overall the quantitative and qualitative 
sections achieve slightly different aims – one elucidating the prevalence of glaucoma, and 
the other elucidating the barriers to glaucoma care. Both are important and complement 
each other. 
Quantitative Data Analysis  
Description of the Data 
 The quantitative data consists of a cross-sectional dataset of patients attending 
Unite For Sight partner clinic outreaches around Kumasi, Ghana during July 2013. The 
data set consists of 969 individual patients. The age, sex, village/location of the outreach, 
visual acuity of the right and left eye (VAR and VAL), and diagnosis is recorded for each 
patient. The data was gathered from 14 locations, most of them rural villages, with a 
mean number of 69.21 patients at each location and a range of 21 to 142 patients 
(outreaches around Kumasi tended to be smaller than the ones around Accra). There are 
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14 possible diagnoses, and some patients have up to four conditions diagnosed (for 
example, allergies in addition to glaucoma). While this research will look at the 
dependent variable of diagnosis of glaucoma (glaucoma being present or absent), other 
diagnoses available in the data include presence of suspicious disc, traumatic glaucoma, 
pterygium, allergies, cataract, immature cataract, phakia, presbyopia, refractive error, 
macular degeneration, macular scarring, age-related macular degeneration (ARMD), and 
corneal scarring. 
Demographics of the Patient Population 
The mean age for the patients is 47.79 years, with a standard deviation of 21.83 
years and a range from 1 year to 100 years. I first broke down the age data is into three 
age categories (25 years and younger, 26 to 49 years, and 50 years and above). The 
results are visible in Table 1, with 50.05% of the patient population in the 50 and older 
age category. The reason for this initial breakdown is because the optometrist in Kumasi 
recommended that those 25 and under with glaucoma get an eye check every year, those 
26 to 49 with glaucoma get an eye check every 6 months, and those 50 and above with 
glaucoma get an eye check every 3 months. 
Another way I looked at age is by much narrower categories, similar to the way 
age has been broken down in other glaucoma prevalence studies in Ghana (Ntim-
Amponsah et al 2004b) (Budenz et al 2013). Both Ntim-Amponsah and Budenz only 
looked at glaucoma in those over 30 years old, either by decade or by 5-year increments.  
One way I chose to look at age is in eight 10-year increments, as per the Budenz et al 
2013 study; the 5-year increments in Ntim-Amponsah et al 2004b were too narrow and 
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not enough cases were present in each category. With the 10-year increments, I chose to 
divide the patient population into 8 categories of those 20 and younger, 20-29, 30-39, 40-
49, 50-59, 60-69, and 70-79, and 80 years and above. This allowed for some balance of 
cases within each category. The results of dividing the patient population into 8 
categories are visible in Table 2. Note that there are a total of 942 patients with data for 
age, although the dataset contains 969 patient names.  
The sex distribution of the patient population is 43.14% male and 56.86% female. 
This sex distribution varies statistically significantly by the three age categories (Chi 
square=9.44, p=0.009). The sex distribution varies insignificantly by the eight age 
categories, but it varies weakly significantly when reducing the number of categories to 
six (to see if significance can be found if slicing the age categories differently), with 29 
and under, 30-39, 40-49, 50-59, 60-69, and 70 and above being the six categories (Chi 
square=10.74, p=0.057). The total sex distribution and distribution by the significant age 
categories is visible in Table 3. 
Measuring Visual Acuity 
 Visual acuity is measured for the right eye (VAR) and the left eye (VAL) and is 
labeled from 6/6 (normal vision) to 6/9, 6/12, 6/18, 6/24, 6/30, 6/36, and 6/60 (decreasing 
vision). A VAR or VAL of 6/6 means that the given eye can see at 6 meters what an eye 
with normal vision can see at 6 meters. A VAR or VAL of 6/60 means that the eye can 
see at 6 meters what an eye with normal vision can see at 60 meters. Someone with 6/60 
vision is considered legally blind in the United States, although level of impairment is not 
absolute, but is relative to the life demands and impact on life quality for the individual 
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(Trinity University 2014). For patients who cannot see at 6/60, visual acuity is recorded 
as CF5M, CF4M, CF3M, CF2M, and CF1M. Such patients can count fingers at 5 meters, 
4 meters, 3 meters, 2 meters, or 1 meter, respectively. For patients who cannot count 
fingers at 1 meter, HM (perceiving hand motions), PL (perceiving light), or NPL (not 
perceiving light) is used. Because young children are unable to read an eye chart, their 
visual acuity is not recorded. See Figure 1 for an approximation of vision with different 
acuities.  
Visual Acuity of the Patient Population 
 For the right eye (VAR), 42.41% of patients have 6/6 (normal) vision. 80.80% 
have a VAR of 6/36 or better, while 15.07% have a VAR of 6/60 or worse and are 
considered legally blind in the US. The remaining 4.12% are children (who are unable to 
read a visual acuity chart). It is important to note that comparing visual acuity between 
eyes (i.e. VAR versus VAL for a given patient) is beyond the scope of this thesis; 
however, patterns of visual acuity for the left eye are similar to patterns for the right eye. 
The visual acuity of the patient population is shown in Table 4. 
Prevalence of Glaucoma 
Glaucoma and Other Diagnoses 
Glaucoma was diagnosed in 28.17% of the patients, with only allergies being 
more prevalent at 48.61%. Presbyopia comes in third (27.45%) and cataract comes in 
fourth (11.25%). Some patients have multiple conditions, and this is why these figures 
add up to over 100%. The distribution by diagnosis is shown in Table 5. 
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Demographics of Glaucoma 
Patients who have glaucoma are 51.10 years old on average, with a wide standard 
deviation of 20.03 years. Patients who do not have glaucoma are 46.50 years old on 
average, with a standard deviation of 22.38 years. Using a t-test shows that the 
differences in age between those with and without glaucoma are statistically significant 
(t=-2.96, p=0.0016). Looking at glaucoma by three categories of age using chi-square 
analysis shows the differences by category to be weakly significant (Chi square=5.43, 
p=0.066). Looking at glaucoma by eight categories of age (19 and under, 20-29, 30-39, 
40-49, 50-59, 60-69, and 70 and above) is likewise weakly significant (Chi square=13.22, 
p=0.067). The significant results are visible in Table 6. 
The prevalence of glaucoma does not differ statistically significantly by sex (Chi 
square= 0.065, p=0.799). When looking at glaucoma’s relationship to sex for each of 
three age groups, the results are not statistically significant either. However, when 
looking at glaucoma’s relationship to sex for each of the eight age groups, there is a 
significant difference in glaucoma prevalence only between males and females for the 40-
49 age group (Chi square=4.29, p=0.038). In this age group, 22.89% of males but 37.36% 
of females have glaucoma. It is only in this age group that the prevalence of glaucoma 
differs significantly by sex, something future research should look into. 
We can also examine how variables such as age and sex influence the likelihood 
of having glaucoma using logistic regression. Linear regression is not used because this 
requires a continuous dependent variable, whereas having glaucoma (or not) is a 
categorical/dummy variable. Using logistic regression, each additional year of life 
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increases the chance of glaucoma by 0.99%, and this is highly significant at p=0.003. 
When looking at age according to the three age categories, an increase in age from the 
under 25 to the 25-50 age category increases the likelihood of glaucoma by 50.47%, 
although this is not highly significant (p=0.066). Moving from the under 25 to the 50 and 
older category increases the likelihood of glaucoma by 61.38%, and this is strongly 
significant at p=0.021. These results hold when controlling and not controlling for sex, 
which is not significant for the probability of having the glaucoma outcome.  
Similarly, looking at the likelihood of having glaucoma by eight age categories, 
all of the categories are significant. Moving from the 19 and under category to the 20-29 
category increases the chance of glaucoma by 137.96% (p=0.010). Moving from the 19 
and under age category to the 40-49 age category increases the chance of glaucoma by 
136.52% (p=0.027). Moving from the 19 and under age category to the 70-79 age 
category increases the chance of glaucoma by 139.99% (p=0.005), and it is only for the 
80 and over category that moving from 19 and under to 80 and over increases the chance 
of glaucoma by 219.99% (p=0.004). Thus, the chance of glaucoma jumps when 
transitioning from the under 19 category to the 20-29 category, and stays roughly the 
same until the 80 and over category. Thus, the change in the chance of getting glaucoma 
relative to age is not linear, but increases quickly early in life and then later in life. 
 The prevalence of glaucoma differs significantly among the 14 village sites (Chi-
square=30.61, p=0.004) (Table 7). The prevalence of glaucoma ranges from a low of 
15.05% in Kwanwoma to a high of 38.71% in Asamang. When looking at such villages 
that have a very high and relatively low prevalence, this may be partly explained by the 
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age distribution of the patients attending the village outreach. In Kwanwoma, which has 
the lowest prevalence of glaucoma at 15.05%, 44.09% of the patients are 50 and older. In 
Asamang, 70.97% of the patients are 50 and older, and the prevalence of glaucoma is 
38.71%. The breakdown of each village/outreach by each of the 6 age groups is shown in 
Table 8. However, none of the relationships between glaucoma diagnosis and age group 
(when age is divided into three groups) are statistically significant, when bysorting by 
village. When bysorting by three age groups, there is a statistically significant difference 
in the relationships between prevalence of glaucoma by village/location only for the 25-
50 age group (p=0.016); glaucoma diagnosis by village via the other two age groups are 
not statistically significant. When sorting by six age groups (as eight age groups show no 
significance anywhere), there is a statistically significant difference in the relationship 
between prevalence of glaucoma by village/location only for the 40-49 age group, but 
there are not enough cases in many of the villages for this age group to make the result 
reliable (Chi square=24.79, p=0.025) 
When looking at the relationship between prevalence of glaucoma and 
village/location by sex, there is no statistically significant difference for either males or 
females.  
 The prevalence of glaucoma does differ statistically significantly by visual acuity 
level, by both VAR (Chi square=48.25, p=0.000) and VAL (Chi square=36.15, p=0.010). 
The prevalence of glaucoma at each level of VAR and VAL is shown in Table 9. 
Looking at the distribution of glaucoma across different visual acuity levels, 23.60% of 
patients with a VAR of 6/6 have glaucoma, and this increases to 44.44% for patients 
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perceiving hand motions and 45.45% for patients not perceiving light. A similar 
trajectory is seen for the left eye, with 26.42% of patients with glaucoma having 6/6 
VAL.  
Quantitative Discussion 
Several interesting insights can be gathered from the data which have implications 
for how glaucoma can be addressed, particularly in Ghana. Most obvious is the fact that 
glaucoma is very common at Unite For Sight partner clinic outreaches in Kumasi, Ghana, 
in that 28.17% of patients in July 2013 were diagnosed with glaucoma. Of course, this 
cannot be extrapolated to represent the prevalence within the Ghanaian population, since 
the patients attending the clinic are not a random sample and are self-selecting in that 
they choose to come to an outreach perhaps because of a known eye condition or even a 
pre-existing glaucoma diagnosis. However, this statistic is important for how outreaches 
may be structured to better address the needs of patients who are diagnosed with 
glaucoma at Unite For Sight partner clinic outreaches in the future. The bias in this 
patient population also shows the difficulty of understanding prevalence, which makes 
understanding and thus diagnosing and treating glaucoma difficult. Only random-sample 
population-wide studies should be used for larger policy decisions regarding glaucoma. 
Another very interesting and important observation is that glaucoma is highly 
prevalent in younger age groups, which is unusual, as glaucoma is thought to afflict 
mostly older individuals. 21.23% of the 25 and younger age group has glaucoma, and this 
is emphasized by the existence of a separate diagnosis of a suspicious disc, which is an 
early sign for glaucoma. This suspicious disc diagnosis, present in 7.26% of the 25 and 
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younger patients, tempers the likelihood of over-diagnosing glaucoma and suggests that 
glaucoma is truly present in such young patients. This knowledge should be incorporated 
into who is targeted by the community liaisons for outreaches, and about how glaucoma 
is presented in health talks – it is clearly not a disease that impacts only the elderly.  
In addition to the young age of glaucoma patients, visual acuity (particularly a 
normal state of it) is not a good predictor of the likelihood of glaucoma. 23.60% of 
patients with a visual acuity of 6/6 (normal vision) have glaucoma, although this 
percentage increases greatly to 45.45% in patients who are NPL (not perceiving light). 
Still, the 23.60% figure illustrates the asymptomatic nature of glaucoma progression, as 
central vision remains normal until the late stages of disease (see Figure 2). Thus, a 
simple visual acuity test alone, without an optic nerve exam or perimetry (testing 
peripheral vision) can miss glaucoma diagnosis. Thus, a comprehensive exam should be 
emphasized, and patients should never be told that perfect vision means perfect eye 
health. 
The fourth finding of the data is that glaucoma prevalence varies highly 
significantly from village to village, from 15.05% to 38.71%. However, this can 
potentially be explained by different age distributions at different outreaches. Preliminary 
mapping of the outreaches showed no geographic pattern in glaucoma prevalence by 
location. Thus, further research into locality-specific differences of glaucoma prevalence 
should be carried out. 
The last finding is that sex does not seem to matter for the glaucoma diagnosis – it 
is equally prevalent in both sexes, even when controlling for age. This finding is quite 
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interesting and shows that, unlike many conditions, both males and females, of all ages, 
and of all visual acuity levels should be equally targeted by outreach efforts.  
Limitations 
 This dataset is highly limited in that it is cross-sectional, only encountering a 
patient at a given moment in time without additional data from previous or past 
encounters with eye care professionals. This limits the ability to understand the 
progression of glaucoma in patients. The data was gathered from July 2013, and it is thus 
limited temporally to patients who attended outreaches at that time. It is unknown if data 
from other months would have yielded different results. It is not a random sample, but 
rather a self-selecting patient population. Additionally, the data is obtained from work 
done by one eye care professional working in a geographically limited area. The 
optometrist was also highly passionate about glaucoma and may have been over-
diagnosing glaucoma, and the impact of this is unknown. Concerns about potential over-
diagnosis are, however, somewhat controlled by the possibility of suspicious disc 
diagnosis and variation in glaucoma prevalence from village to village.  
All of these limitations in the data curtail our ability to extrapolate to other 
regions of Ghana, not to mention other parts of West Africa. Another limitation is the 
inability to know whether patients attending a certain outreach actually originate from 
that village, or if they traveled there for the outreach. This limitation introduces bias into 
any connections being made between location and glaucoma prevalence. 
Another limitation of the data is that only a few variables are available for 
analysis. For the purpose of studying glaucoma, it would be useful to know if there is a 
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family history of glaucoma and if the patient has ever had an eye checkup. Other more 
general demographic factors of interest would be the education level, occupation, and 
income, as these may relate to access to eye care and thus to progression of glaucoma. 
Data on the components of the glaucoma diagnosis (for example, intraocular pressure 
measurements, visual field test scores, and optic disc to cup ratio measurements) would 
have greatly enhanced the analysis by allowing for an ability to study the conclusiveness 
of the glaucoma diagnosis. 
Qualitative Data Analysis 
Barriers to Understanding Prevalence 
 I define barriers to understanding prevalence as the process before any outreaches 
occur – in the more general understanding of the problem of glaucoma. A 
misunderstanding of prevalence precedes the lack of diagnosis and treatment of 
glaucoma. In short, both programs and patients are unaware of how prevalent glaucoma 
is. Barriers to understanding prevalence are mostly program-side, although patients 
contribute to misunderstanding prevalence by not attending health talks and by general 
lack of health/eye care education in patients. 
Program-side, there is a lack of research on glaucoma by Unite For Sight, which 
has a Global Impact Lab that assigns interested volunteers a research project. 
Additionally, the decision-making power over research questions, which are obtained 
from the partner clinics – of the players who are most in contact with glaucoma patients 
and those who make decisions on research studies – make glaucoma a less emphasized 
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disease compared to cataract. Additionally, the structure of the outreaches makes research 
difficult, since poor (or no) recordkeeping makes data analysis problematic. 
 Understanding Prevalence: Program-Side Barriers in Ghana and India 
  Structural/Economic 
 One big program-side problem is the lack of substantial studies on glaucoma by 
Unite For Sight volunteers, who can participate in a research study during their 
volunteering via the UFS Global Impact Lab. Out of 86 research studies listed on Unite 
For Sight’s Global Impact Lab’s page of past research studies, only 7 address glaucoma 
directly (UFS 2013c). In the Global Impact Lab, volunteers (often students who have a 
research background) are given a research assignment – a research question that has been 
asked to be studied by the partner clinic. I was initially a researcher evaluating the eye 
care knowledge of informal volunteers – community members who help out during 
outreaches without any formal affiliation with UFS or the local partner clinic. Upon 
arrival in Ghana, my research question was met with quizzical looks by other volunteers 
as well as local Ghanaian clinic staff:  
[The optometrist] was surprised by the topic – apparently she hasn’t seen 
many informal volunteers on outreaches. One of the other volunteers 
commented that he has seen patients volunteer, for the sake of making the 
outreaches go faster. So, as of right now, I am worried about my research 
project – what if there aren’t any informal volunteers to interview? (Ghana 
Blog, July 21
st
, 2013) 
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 In other conversations with volunteers, I heard of others doing similar research 
projects that they felt to be disconnected from the reality in Ghana. While I did as much 
of such a research project as I could, I found glaucoma to be a real pressing issue. 
However, it does not seem that glaucoma is an issue being studied deeply by the UFS 
Global Impact Lab (as mentioned previously, seven studies have been done on glaucoma 
by UFS volunteers in the past). This contributes to the barriers to understanding 
glaucoma prevalence.  
 Once a study of glaucoma prevalence is attempted, I can foresee one major barrier 
to doing such research, related to the program structure. Outreaches in Chennai have 
absolutely no recordkeeping. Certain Ghanaian outreaches keep sporadic records, and 
only one outreach (out of dozens) keeps information on each patient longitudinally, from 
outreach to outreach. This makes studying prevalence and other aspects of glaucoma 
(such as treatment outcomes) extremely difficult (although this research could better be 
considered incidence research, as it is the number of glaucoma cases per group of patients 
who come to the outreaches). While research via UFS outreaches certainly may not be 
random and does not represent the population of Ghana, it is still helpful for 
understanding the needs of the patients who attend UFS partner clinic outreaches. The 
poor or lack of recordkeeping at outreaches makes it difficult to understand such 
prevalence/incidence and glaucoma treatment outcomes.  
 As mentioned in the literature review, there is also a lack of population-wide 
research studies on glaucoma prevalence (one such study specific to Ghana, still deemed 
“incomplete”, and five such studies in India). Such population-wide studies are the 
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responsibility of larger institutions of learning and international organizations and 
governments; thus, a concerted approach both by organizations such as UFS and by 
larger organizations and governments is needed to better understand glaucoma incidence 
and prevalence in both India and Ghana. 
  Psychological/Socio-cultural 
 Looking at the types of studies done via the UFS Global Impact Lab perhaps 
suggests that partner clinics are not requesting research studies about glaucoma 
prevalence. This may occur for many reasons. One reason is that the local clinics are 
unaware of glaucoma and how prevalent it is, or may see such prevalence as normal and 
expected and not something to question or study. Another explanation is that there is a 
mismatch in who assigns/suggests research questions and who is in closest contact to the 
patients. It seemed to me that it was the ophthalmologist at each clinic who decided on 
the research study topics. However, it is the optometrists who go to the outreaches daily, 
as the ophthalmologists (in both Ghana and India) stay in the clinic. Lack of 
communication or a distant relationship between optometrists and ophthalmologists may 
be leading to a lack of research on glaucoma prevalence. This may be reinforced by a 
partner organization such as Unite For Sight subsidizing and, thus, emphasizing cataracts 
or other conditions over glaucoma. 
 However, one Ghanaian clinic worker was indeed very interested in 
understanding glaucoma prevalence, and spoke to me about doing an analysis of 
glaucoma prevalence from the patient data that is available: 
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[S/he] is seeing an increasing number of young people with glaucoma, 
which worries [him/her]. [S/he] wants to understand why it is so prevalent 
among people of some villages but not others – [s/he] believes that it is 
due to genetic factors, where there is a lot of intermarriage within certain 
villages. (Ghana Blog, July 26
th
, 2013) 
 Such individuals help reduce the barriers to understanding glaucoma prevalence, and 
certainly need larger institutional support via further research. 
 Understanding Prevalence: Patient-Side Barriers in Ghana and India 
  Psychological/Socio-cultural 
 Patients being late to the outreach and missing a health talk means that they do 
not learn about glaucoma and its prevalence in the population. Only Ghanaian outreaches 
do such health talks, so patients in Chennai do not have access to understanding about 
glaucoma prevalence because of a lack of a health talk. It is beyond the scope of this 
thesis to determine whether patients obtain education about glaucoma from other sources; 
certainly lack of education – whether from UFS or from other sources – contributes to 
patient-side barriers to understanding prevalence. 
Barriers to Diagnosis 
 In this section, I report on the barriers to glaucoma diagnosis. I define diagnosis 
broadly – from getting the patient to attend the outreach to the patient going through the 
outreach screening process all the way until contact with the optometrist or other 
clinician occurs, leading to the diagnosis. Barriers to diagnosis occur at both the program-
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side level as well as the patient-side level. Program-side barriers include the geographic 
distribution of outreaches; lack of access to other eye health care facilities unaffiliated 
with UFS-partner clinics; requiring patients to pay a fee to participate in the outreach 
(used to pay for the community liaison’s advertising for the outreach); referrals to an 
ophthalmologist rather than diagnosing the patient at the outreach; different clinic staff 
emphasizing and being aware of glaucoma to a different extent. Patient-side barriers 
include time and cost of traveling to and time spent at the outreach (and opportunity costs 
associated with each); financial payments at the outreach; the locations of outreaches at 
churches; other social obligations that take priority over eye care; misunderstanding the 
role of glasses versus comprehensive screening and eye medication; difficulty of 
accepting an asymptomatic and early-onset diagnosis; language barriers between 
staff/volunteers and patients. Reductions of barriers to diagnosis include community 
liaisons who advertise about the outreach and help in patient registration and in-take; 
targeting multiple, different villages during each outreach to a location; comprehensive 
eye checks (rather than only screening for cataracts); health talks that inform and make 
acceptance of a diagnosis potentially easier.  
 There are large differences in the barriers to diagnosis of glaucoma in Ghana 
versus India. The programs are very different in their level of addressing barriers to 
glaucoma care. As such, some actions that are taken in Ghana can be considered a 
reduction in barriers to glaucoma diagnosis, but the same barrier-reducing actions may 
not be taken in Chennai, India. This difference from country to country serves to 
reinforce the importance of being specific about the analysis of barriers to glaucoma care 
 57 
 
– different programs have different barriers and are addressing the barriers differently. 
No single solution can be used for all locations.  
 Diagnosis: Program-Side Barriers in Ghana and India 
  Structural/Economic 
 One barrier to diagnosis is that the location of outreaches is determined by the 
outreach clinic having a connection to someone in the community. Thus, communities 
that may have high rates of glaucoma may not be visited by the outreach clinic at all, 
because of lack of a community liaison. Perhaps the next steps in reducing this barrier to 
diagnosis would be to ensure that outreaches are geographically well-distributed and 
reach all communities. However, it is unknown if other organizations may be functioning 
in other areas, so perhaps this barrier maybe overstated. Regardless, this is too large of a 
feat for a non-profit organization or clinic and is instead something the Ghanaian 
government or larger entities should be responsible for. In India, the outreaches were 
additionally solely concentrated in urban areas around Chennai, thereby eliminating the 
possibility of diagnosis via UFS partner clinics for patients living in rural areas, who are 
more likely to be poor and have low access to eye care. 
 Other barriers to diagnosis occur in the lack of access to other healthcare facilities 
that can provide a diagnosis, other than the outreach. For example, one clinic still holds 
outreaches to an area that actually has an eye clinic because, as a Ghanaian optometrist 
explained, “a consult at the relatively nearby clinic is 15 cedi and the eye drops are twice 
as expensive as at our outreach” (Ghana Blog, July 23rd, 2013). Thus, the lack of 
affordability within the local healthcare infrastructure is a barrier to diagnosis of 
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glaucoma (and also a barrier to treatment, as patients require regular check-ups for their 
glaucoma). In Chennai, I was surprised that outreaches were held in urban areas given the 
high concentration of eye clinics, but, similarly, this was because the outreaches served 
people who otherwise cannot afford to get screened at local facilities. 
 There was one potential reduction in the barrier to diagnosis in that some clinics 
provided a stipend to the local community liaison/worker for recruiting patients. Some 
clinics collected 1 cedi from the patients attending an outreach and this provided the 
stipend for the liaison with the following effects: 
The community worker took 1 cedi from each patient (this was his 
payment, and also compensation for any money he spends on publicity). 
He spends two weeks publicizing daily (3 cedi for a daily community 
announcement, for example), so he really loses when patients don’t show 
up. (Ghana Blog, July 31
st
, 2013) 
As such, the liaison has an incentive to maximize the patient turnout at the outreach, 
thereby allowing for a reduction in barriers to glaucoma diagnosis. Other clinics provided 
a payment for each patient referred for cataract surgery (rather than per patient attending 
the outreach), so liaisons in such community obtained less remuneration for their 
advertising. In either situation, the community liaisons had an incentive to attract as many 
people to the outreach as possible. However, any fee to participate in the outreach could 
have also deterred patients from going through with the screening, even if they decided to 
come to the outreach. Additionally, not all outreaches provided a payment to the liaisons 
(regardless of how many patients showed up, as policies seemed to differ by location); 
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several outreaches would have turnouts as low as 40 patients, because the community 
liaison would not do a good job at recruiting. Thus, the economic incentives given or not 
given to community liaisons had differing effects on barriers to glaucoma diagnosis. 
 Another aspect of the program can be seen as both a reduction of barrier to 
diagnosis but also an increased barrier to treatment. One nurse in Ghana explained that a 
different set of neighboring villages is targeted during repeated outreaches to the same 
location. More people have a chance to get diagnosed when multiple different villages are 
targeted, but this provides a barrier to treatment for returning glaucoma patients, who 
have to keep track of changing community liaisons and the varying modes of 
advertisement about the outreaches. The clinic driver in Chennai similarly explained that 
the outreaches in India constantly target a different area or urban location. This increases 
the likelihood of diagnosis by allowing for a basic eye check and referral to an 
ophthalmologist, but also presents a challenge to treatment (although outreaches in India 
do not diagnose or treat glaucoma in the first place because of optometrists’ practice 
limitations). 
 Another reduction of barriers to diagnosis was seen with the help of the liaison 
and other members of the community during the outreach. At many outreaches, upon the 
clinic’s arrival, the community liaison and various assistants or community members 
would already be doing registration and visual acuity. This reduced the waiting time 
during the outreaches (which usually was very long and took several hours at the least), 
thereby increasing the chance that a patient would wait their turn to see the optometrist 
and get the diagnosis. However, the very size of some of the outreaches (in the hundreds 
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of patients) meant that people may have left the outreach before getting diagnosed, 
although I did not observe this happening – patients seemed to wait their turn. Still, the 
size of the outreaches can be seen as a barrier to diagnosis (and treatment, for those 
returning for a checkup). 
 The comprehensiveness of outreaches in Ghana also reduced the barrier to 
glaucoma diagnosis. All patients in Ghana had their optic nerve observed to check for 
glaucoma. However, this was not the case in Chennai, as the outreaches only checked for 
cataract, refractive error, or presbyopia and did not check the optic nerve. This is partly 
related to the fact that optometrists in India are not legally permitted or qualified to 
diagnose advanced eye conditions such as glaucoma, and must refer such cases to an 
ophthalmologist. Optometrists in Ghana, on the other hand, all used a direct 
ophthalmoscope to check for glaucoma, whereas such equipment was not present at the 
outreaches in India. Instead, advanced cases in India would be identified with the pinhole 
test, which uses a particular set of lenses to correct vision problems caused by errors in 
focusing. All other conditions not caused by errors in focusing (such as diabetic 
retinopathy, glaucoma, age-related macular degeneration, etc.) would not be corrected by 
the pinhole test, and this would be the red flag for the optometrist to refer the patient to 
an ophthalmologist. However, in India, “patients who were 6/6 or 6/9 were told that they 
were normal without further examination [i.e. without the pinhole test] and were told they 
could leave, unless they had another complaint that was bothering them that they wanted 
to address” (India Blog, January 9th, 2014). Thus, patients who presented with normal 
vision in Chennai often did not undergo the pinhole test and thus early stages of 
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glaucoma (when it is asymptomatic and vision is still perfect) do not get diagnosed in 
India. In Ghana, patients with 6/6 vision still underwent the entire clinic process and had 
their optic nerve checked for glaucoma. 
In India, for those who do obtain a pinhole test and still have problems seeing and 
are suspected to have something other than cataracts, the optometrist refers the patient to 
a nearby ophthalmologist. As the ophthalmologist in Chennai told me, nearby 
ophthalmology practices are referred to in order to not offend local doctors. However, it 
is unknown how many patients follow through with such referrals, highly problematic for 
asymptomatic glaucoma cases: 
I was really frustrated throughout the outreach about how non-
comprehensive the camp[i.e. outreach] is. It basically only looks for 
cataracts. This means that many patients walk away thinking that they are 
completely fine when, in fact, they might have an asymptomatic condition 
and are not getting properly checked. I am not sure if I buy the whole idea 
that they should just instead go to their local hospital – they won’t if they 
don’t have the money, and now they have had false reassurance that there 
is nothing to worry about. I know glaucoma isn’t highly prevalent [in 
India], but still, in an outreach to 50 people, if 1 person has glaucoma, that 
is 1 potentially and irreversibly blind person. That is a tragedy. (India 
Blog, January 9
th
, 2014) 
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 Psychological/Socio-Cultural 
Daily observations of the various clinic staff in Ghana suggested conflict among 
staff which might reduce the effectiveness of the program. Different members of staff 
occasionally had differing views on what is important for the program to address, and this 
manifested in different clinics emphasizing glaucoma to a different extent. Some 
optometrists had a strong emphasis on glaucoma, while other staff members did not did 
not feel so passionate about this particular condition. However, some optometrists may 
have also been over-diagnosing glaucoma, possibly because the interpretation of nerve 
damage can be somewhat subjective as optic nerve structures differ from person to 
person. Conversely, optometrists who are not particularly looking for glaucoma may 
under-diagnose it. Also, there was usually one optometrist at each outreach who made the 
final diagnosis, and a second opinion was not available. However, one clinic in Ghana 
did have two optometrists/ophthalmic nurses at their outreaches and they occasionally 
collaborated on an unclear case. Additionally, some clinics emphasized glaucoma 
screening as part of a larger comprehensive screening process because, as one optometrist 
explained, not providing comprehensive treatment lowers the credibility of the outreaches 
and the clinic. The complex motivations for providing diagnosis are outlined in this entry: 
[The optometrist] explained that simply giving [a patient] reading glasses 
would have 1) not stopped her glaucoma from progressing and 2) would 
have tarnished [the clinic]’s and [the optometrist]’s reputation as being 
irresponsible and of not fully diagnosing the woman. Thus, it is important 
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for all patients to go through a full screening before they get any 
medication or glasses. (Ghana Blog, July 29
th
, 2013) 
 Thus, possible challenges to a clinic’s or optometrists’ reputation in Ghana 
certainly encouraged comprehensive care, including checking for glaucoma. 
Observations on this issue were not made in India. 
 Diagnosis: Patient-Side Barriers in Ghana and India 
  Structural/Economic 
 One very common barrier to diagnosis for virtually any health problem is the 
distance patients have to travel for treatment; patients in Ghana came from various 
villages of different distances, although I was not able to assess how far away such 
villages are. Such travel poses financial burdens on the patient, as well as opportunity 
costs of taking the time out of their day to travel that they could instead be used for 
economic or other important activity.  Even without travel, patients often spent the 
majority of a day at the outreach, which perhaps deterred future visits to the outreaches 
by the patients, and discouraged new patients from attending, given that the length of 
time spent waiting would certainly become known in the community. Sometimes, the 
influx of patients traveling from different areas was unexpected, as seen in this entry:  
Apparently, about 200 of the patients today were refugees from Cote 
d’Ivoire, as there is a refugee camp about ten minutes away from the site 
where we did the outreach. [The optometrist] explained that there was 
post-election violence in Cote d’Ivoire two years ago, and some people 
were displaced to Ghana. (Ghana Blog, August 14
th
, 2013) 
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Such days with large numbers of patients posed other key barriers to diagnosis: 
the optometrist had a limited amount of time to spend with each patient and was possibly 
more likely to misdiagnose due to increasing fatigue. This was made more complicated if 
there were language barriers between patients and providers. 
Another barrier to diagnosis was when outreaches had registration fees used to 
cover advertising costs and to serve as financial incentive for the community liaisons. I 
observed such fees discouraging several (often young) patients who did not have an 
income and were often asymptomatic from getting a check-up, and this was likely a 
barrier to glaucoma diagnosis. Several such young patients simply left the outreach 
without getting screened, because they realized there was a cost to get a check-up. 
  Psychological/Socio-Cultural 
 In addition to the economic or structural barriers to obtaining a glaucoma 
diagnosis, a variety of psychological or socio-cultural factors were potential barriers. One 
example is that Ghanaian outreaches were nearly always held in Christian churches. 
While there were many Muslims and Christians present at each outreach, the carrying out 
of outreaches in churches may have made certain members of the community 
uncomfortable and may have prevented outreach attendance (although I did not observe 
this directly). One optometrist explained to me that outreaches could not be carried out in 
mosques because the Christians would not attend; Muslims came to Christian churches 
for outreaches, however. In India, the outreaches were typically held in schools and 
community gathering places, and did not have this potential barrier. 
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 Another barrier to diagnosis was the opportunity costs related to attending social 
functions or community events versus going to the outreach. Repeatedly seen in Ghana, 
large groups of patients were late to the outreach by hours because of a funeral in the 
community. Sometimes, various local conditions such as these meant that an outreach 
was cancelled or that very few patients attended the outreach. This infuriated one 
optometrist very regularly, because she disagreed with the prioritization of such socially 
important events over eye health. 
 Another highly prevalent barrier to diagnosis of glaucoma is the belief that glasses 
will cure everything. In short, patients in both Ghana and India did not see the importance 
of a comprehensive eye check. Even important members of the community who serve as 
role models and are affiliated with the outreaches had such curative notions about 
glasses: 
A community member who works at the local radio station showed up to 
get a pair of reading glasses. He had disseminated information about the 
outreach to the public. [The optometrist] was very upset that [the man] 
decided to show up at the end of the outreach, and that he simply wanted 
reading glasses. She explained that patients often get reading glasses when 
they actually have another underlying condition causing their vision loss. 
(Ghana Blog, July 29
th
, 2013) 
 The optometrist explained that this misunderstanding stems from a lack of 
education about eye care, and this is something the clinics in Ghana try to counter via the 
health talks. Additionally, since patients tended to believe they do not have glaucoma if it 
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is asymptomatic and early-onset, the health talks provided information that would 
promote acceptance of the asymptomatic and early-onset glaucoma diagnosis. 
 Another barrier to diagnosis was the constant language barrier between patients 
and the clinic workers and volunteers. This was highly prevalent in Ghana, where 
different regions speak different local languages. Similarly, in Chennai, several patients 
came in speaking only Hindi, whereas the clinic workers only speak Tamil. Such 
language barriers made every stage of the outreach complicated, from the initial health 
talks in Ghana, to the screening, to explaining the treatment. This was handled in a 
variety of ways – from having someone in the community translate, to using various hand 
gestures to communicate. 
Barriers to Treatment 
In this section, I report on the barriers to glaucoma treatment. I define treatment as 
the process that takes place after diagnosis has been obtained. Of course, this barrier to 
treatment is only applicable to situations where diagnosis is attainable (for example, 
barriers to treatment are observed in Ghana, but not in India, because glaucoma is not 
diagnosed at the outreaches). Barriers to treatment typically occur at either a program-
side level or at a patient-side level. Program-side level barriers to treatment occur with 
reduced access to outreaches given the infrequency, location, and advertisement of 
outreaches; reduced access to medication because of medication pricing at outreaches; 
lack of longitudinal patient data keeping; the presence of “siloing” in programs; various 
interpersonal barriers among the clinic employees and volunteers contributing to barriers 
to treatment of glaucoma. Patient-side barriers to treatment are also discussed, such as 
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inability to afford medication, distance of travel to the outreach for repeat check-ups, 
misunderstanding of the purpose of medication versus glasses, attitudes toward 
asymptomatic conditions, and language barriers between patients and clinic employees 
and volunteers. Reductions of barriers to treatment are also discussed, particularly with 
the use of health talks.  
It is important to know that the barriers to glaucoma treatment differed widely 
from country to country – the barriers in Ghana are very different from the barriers in 
Chennai, India. Thus, the section goes back in forth in comparing the barriers to 
treatment in Ghana versus Chennai. Additionally, some barriers may be reduced in one 
location, but are not addressed in other locations. Such comparison serves to highlight the 
importance of locality-specific treatment and understanding that a single set of solutions 
certainly will not remove barriers to treatment in all areas. The programs are very 
different in terms of progress toward eliminating various barriers to treatment.   
 Treatment: Program-Side Barriers in Ghana and India 
  Structural/Economic 
 One barrier to glaucoma treatment in Ghana resulted from the outreach clinics not 
returning to the same location frequently enough to provide the medication needed. 
Outreaches in Ghana returned to some villages every 3 months, for example. However, 
the standard supply of glaucoma medication usually lasts for a month. Patients would 
have to have the foresight and economic capacity to purchase three months of medication 
in advance. Also, some patients with advanced glaucoma may require care that is more 
frequent than once in 3 months. According to the Chennai, India driver, their outreaches 
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did not return to the same location twice (and did not sell/provide glaucoma medication). 
Thus, it is foreseeable that infrequently visited locations, not visiting the same location 
twice, and not selling medication at the outreaches would have no or reduced access to 
glaucoma treatment. Since non-adherence to a glaucoma treatment regimen is already 
high in communities with ready access to medication (for example, only about 56% of 
patients use more than 75% of the expected doses in the US), not having access to the 
medication in Ghanaian communities is an additional burden that prevents treatment. 
Proper treatment otherwise “reduces the development or worsening of glaucoma by at 
least 60%” and “poor adherence results in greater visual loss and a higher risk of 
blindness” (Mansberger et al 2013). 
Another barrier to treatment in Ghana is that the same health workers would not 
be used for the same location each time. This occurs because a different set of nearby 
villages is targeted during each outreach, and a different liaison may be needed to reach 
these new villages. Thus, the demographic targeted each time is somewhat different, 
which presents barriers to treatment for patients who require a new supply of medication 
or a glaucoma check-up, as these patients would have to keep track of advertisements set 
up by different liaisons, who may be targeting other locations.  
 For patients who did come back to the same clinic for a second time after several 
months, another barrier to treatment was that longitudinal patient information was not 
available.  Outreaches in Ghana took down patient information for each outreach, but did 
not track patients over time. Only at one outreach in Ghana – at a refugee camp near 
Accra where the same community liaison held patients’ records in between outreach 
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visits – were longitudinal records kept for patients. At another outreach, an entirely 
different scenario unfolded, where returning patients were not entered into the Excel 
database at all. At the Chennai, India outreaches, no patient information was taken down. 
Because of these differences and gaps in patient data, patient history could not be 
available for comprehensive, long-term treatment.  
 Another barrier to glaucoma treatment occurred with the cost of medication (and 
medication was only sold at Ghanaian outreaches, not ones in Chennai). One optometrist 
in Ghana explained to me that the clinic buys the medication wholesale and then sells it at 
no profit to the patients, or 4 cedi. Sometimes, during unanticipated turnouts of patients, 
the outreach would run out of a certain type of medication, making treatment impossible. 
Additionally, medication prices (for the same exact medication) varied from clinic to 
clinic during the outreaches (4 cedi in one clinic and 8 cedi at another), and I found prices 
for the same medication to be lower in pharmacies in Accra (5 cedi). Thus, the pricing for 
medication was unclear. Additionally, I found that ability to provide discounts for 
patients who could not afford the medicine differed from clinic to clinic. Some 
optometrists felt comfortable giving a discount for persistent patients, but other 
optometrists stated that it is up to the ophthalmologist who owns the clinic to give 
discounts. Thus, there were differences in access to treatment for glaucoma based on 
which clinic outreach was attended – there were differences in prices, and differences in 
the ability to obtain discounted medicine.  Unite For Sight, in both Ghana and India, does 
not subsidize glaucoma medication or any other treatment forms for glaucoma (such as 
glaucoma filtration surgery). 
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 I was not able to determine where profits (if any) from medication sales go.  
However, I did find out that some of the clinics have Unite For Sight pay for the gas to 
the outreaches, and UFS pays the salary of some of the optometrists (this differed from 
clinic to clinic). Other clinics have a less close-knit relationship with Unite For Sight and 
do not receive a gas subsidy, and their optometrists are instead employed by the partner 
clinic. It is possible that some of the profits from medication sales are used to pay for 
such expenditures, which differ from clinic to clinic depending on program structure. 
Such differing program structures would have a different impact on the treatment of 
glaucoma.  
 One highly evident barrier to treatment from the program side occurred with the 
“siloing” of programs, particularly notable in Chennai. One way to think of “siloing” is in 
opposition to integration and one where a healthcare system is “one of fragmented 
specialists who deliver discrete interventions as opposed to coordinated and integrated 
care” (Porter et al 2008:3). This is problematic because it does not maximize value in 
healthcare in terms of “patient health outcomes per dollar spent” – it has many 
redundancies in health expenditure and also has less positive effect on health outcomes 
than comprehensive care (Porter et al 2008:3). In India, the partner clinic had several 
separate programs they were conducting – ones for diabetic retinopathy (working with 
another external organization), cataracts (via Unite For Sight), etc. This “siloing” was not 
as highly visible in Ghana, where the outreaches were rather comprehensive and 
diagnosed as well as treated everything from allergies to cataracts. On the part of Unite 
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For Sight, an emphasis on cataracts (in terms of policy as well as economic subsidy) 
could likewise be interpreted as a form of “siloing.” 
 One barrier to treatment particular to India was that optometrists are not qualified 
to diagnose and treat glaucoma; they are only permitted to diagnose refractive error or 
presbyopia, and make an initial diagnosis of cataracts. Thus, the optometrist used the 
pinhole test (which focuses light on the fovea and compensates for and corrects any 
problems caused by farsightedness/nearsightedness) to flag down advanced conditions. 
Such advanced conditions such as glaucoma, diabetic retinopathy, or macular 
degeneration could not be conclusively diagnosed with a pinhole test and, thus, patients 
failing the pinhole test would automatically be referred to an ophthalmologist. This was a 
barrier to treatment for patients who had to seek an ophthalmologist’s consultation before 
obtaining definitive diagnosis and treatment. However, the outreaches in India also tried 
to refer patients to local/geographically proximal ophthalmologists – this helped the local 
ophthalmologists stay in business, maintained the UFS partner clinic relationships within 
the ophthalmological community in the area, and allowed patients easier access to the 
ophthalmologist in terms of travel distance. In this way, the UFS partner clinic in 
Chennai, India only handled the cataract cases that came in from the outreaches, and 
referred conditions such as glaucoma to the local ophthalmology practices or government 
hospitals. 
 There was one aspect of the program in Ghana that may have reduced barriers to 
treatment – the use of the health talk. While no health talks took place at the Indian clinic 
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outreaches, virtually each outreach in Ghana began with a health talk. Here is an excerpt 
from the blog that characterizes a health talk: 
[The optometrist] began by giving a lengthy health talk, where she 
described many eye conditions, including an emphasis on glaucoma, 
which she made the crowd pronounce back to her several times as she 
explained it… Next, [two of the American volunteers] did a demonstration 
of how to put in eye drops and eye ointment. (Ghana Blog, July 22
nd
, 
2013) 
 The health talk is coded as a reduction to barriers in treatment because the health 
talk occurs after the patients have arrived at the outreach and will go through the outreach 
process. Thus, the health talk educates patients about the diagnosis they may receive, so 
that they are better positioned to understand the importance and method of treatment, an 
integral component of the Health Belief Model. Note, however, that this reduction is not 
universal as the health talks took place in Ghana but not in India.  
  Psychological/Socio-Cultural 
 One socio-cultural barrier to treatment of glaucoma was the outreach program’s 
emphasis on symptoms. Upon arrival at the outreaches in Ghana, patients were asked if 
they had any itching, burning, tearing, etc. This structuring of the outreaches (and of 
medicine in general) reinforced the idea that eye diseases likely have symptoms 
associated with them – which is not true for glaucoma. Furthermore, in India, patients 
who had no symptoms and had 6/6 or 6/9 vision were often told they have normal vision 
and can go home. This lack of comprehensive check reinforced the assumption of no 
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symptoms, no disease. This is highly problematic for glaucoma, which is asymptomatic 
and preserves central vision until the late stages (see Figure 2).  
 Another difference observed from clinic to clinic was the level of involvement 
and passion for the cause of eye care. Some optometrists and clinic workers were 
extraordinarily passionate about treating all conditions, whereas others were very 
ineffective at educating the patients or about being comprehensive in their checkups. 
Such individual-level variables influenced patient treatment outcomes.  
 Lastly, language barriers between clinic employees and foreign volunteers, as 
well as volunteers and patients, often formed another barrier to treatment. Because 
volunteers were actively involved in every step of the outreach process, dispensing 
medications often fell on the volunteers. While there was typically a clinic employee 
around, misunderstandings between volunteers and patients likely occurred and may have 
influenced treatment (i.e. misunderstanding about dosage frequency).  Similarly, 
misunderstandings between volunteers and clinic employees may have compromised the 
quality of treatment.  
 Treatment: Patient-Side Barriers in Ghana and India 
  Structural/Economic 
 One of the most pronounced barriers to glaucoma treatment was the inability of 
some patients to pay for their glaucoma medication, which ranged from 4 to 8 cedi, 
depending on the outreach. Patients who were unable to, or sometimes did not understand 
the importance of, buying the medication were given a piece of paper with the name of 
the medication along with the dosage (not a formal prescription, just a note that even 
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volunteers could write). Patients could then go to a pharmacy and pick up the medication, 
although the distance to a pharmacy posed another barrier to treatment. As mentioned 
previously, patients would sometimes be given a discount, but this depended on which 
clinic’s outreach they happened to attend. Some patients did try to “game the system” by 
appealing to the volunteers for help to pay for the medication; once, when a clinic 
employee denied a discount, the patient was seen taking out a large wad of money to pay 
for the medication. Still, sometimes patients would have to make tradeoffs between 
buying medication for themselves versus for their children, or had other financial 
priorities. In such situations, the health talks were potentially instrumental in the 
prioritization of glaucoma treatment – for example, buying glaucoma drops before buying 
allergy drops, understanding that glasses will not fix glaucoma, or buying glaucoma 
drops versus spending the money elsewhere. 
 The inability to pay for medication varied according to the location of the 
outreach. In one rural location visited, 7 out of 37 patients whom I observed said they 
were not able to buy medication (I did not ask the patients directly – I simply observed 
patients as they interacted with the medication dispenser at the outreach). At much larger 
outreaches in more urban areas, however, I observed almost no people claiming to be 
unable to purchase medication, and patients would buy additional bottles of medication to 
have for the next few months. However, most outreaches were to rural areas, where the 
former situation was much more likely.  Another intersecting factor (other than rural 
location and its connection to income) was age. Patients who were young were often 
asymptomatic, and thus saw no benefit to glaucoma treatment: 
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One was a 19-year-old male with glaucoma, but was asymptomatic. He 
said he did not have any money for the medication and laughed at [the 
nurse] when she tried to explain how important it is that he asks his 
parents for the money. Another 16-year-old male glaucoma patient simply 
did not have the money for the eye drops either. (Ghana Blog, July 22
nd
, 
2013) 
 Another structural and economic barrier to glaucoma care was the distance 
traveled to the outreach. While distance traveled to outreach was a barrier to diagnosis for 
the undiagnosed, it was also a barrier to glaucoma treatment for returning patients who 
must travel great distances to obtain a glaucoma check-up or a new bottle of medication.  
  Psychological/Socio-Cultural 
 One big barrier to the treatment of glaucoma was that many patients arrived late 
to the outreaches, sometimes missing part or all of the health talk. It was routine for only 
half of the patients (or fewer) to be there upon the beginning of the health talk. This 
frustrated one of the optometrists immensely, because such patients would not understand 
the glaucoma diagnosis and would not understand the importance of treatment:  
[The optometrist] was extremely upset at the turnout, because we left 
Kumasi at 6:30am and arrived [at the outreach location] at 9:30am – a 
three-hour drive. One of the community members said that people were 
busy because there were several funerals going on in the past few days, 
but [the optometrist] would not take this as an excuse – she said that this 
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meant choosing a funeral over one’s own eye health. (Ghana Blog, July 
29
th
, 2013) 
 Those who did attend the health talk had the opportunity to not only learn about 
glaucoma but also to observe patients who already completed treatment (typically 
cataract surgery) and hear them testify about their positive outcome. In terms of 
glaucoma, returning patients (who were often blind or having severe vision loss) or newly 
discovered advanced glaucoma cases were used as an example for the asymptomatic 
patients to understand the importance of glaucoma treatment. One such case was used to 
show the importance of glaucoma treatment to the two asymptomatic young men – aged 
19 and 16 – mentioned on the previous page: 
There was a 28-year-old male with advanced glaucoma. He had the ability 
only to detect hand motions with one eye and had 6/60 vision in another 
eye... He bought 2 bottles of Lavamol (glaucoma drops) to prevent his 
eyesight from deteriorating further. (Ghana Blog, July 22
nd
, 2013) 
 Unfortunately, despite this example, the young men were not able to purchase the 
medication and took prescription slips with the eye drop information on them. This 
inability (or declining) to buy medication brings into question the effectiveness of the 
health talk as well.   
 Another psychological and socio-cultural barrier to glaucoma care is the 
previously mentioned belief that asymptomatic conditions are harmless and that eye 
drops are not particularly effective compared to eyeglasses. Eye drops, which are the way 
to treat glaucoma, were perceived to be less efficacious than glasses, and I often observed 
 77 
 
patients who were unable to purchase both their prescribed glasses and eye drop 
medication wanting to purchase only the glasses, even as the medication may have been 
for glaucoma. Thus, in choosing treatment, this tradeoff was made by some patients: 
Some patients bought reading glasses, but not the medication; [one of the 
workers] said that most of the patients who didn’t buy the medication 
simply said they don’t have the money for it and sometimes see glasses as 
an instant fix, and don’t see the medication as necessary or effective. [The 
optometrist] tries to convey the importance of medication in the health 
talks, and the volunteers even do a demonstration of how to put in eye 
drops properly, but some of the patients are not present for [the health 
talk]. (Ghana Blog, July 26
th
, 2013) 
 Additionally, even if the patients are present for the health talk, there is no way to 
be certain that patients paid attention or understood the content being presented during 
the talk. One optometrist in Ghana used visuals (such as a diagram of the eye) to explain 
glaucoma, while others spoke verbally about the disease, and this, for example, may 
affect patient understanding of the health talk.  
 Thus, the psychological and socio-cultural barriers to glaucoma treatment 
combine with structural/economic issues, having components of lack of health education, 
underestimation of the seriousness of asymptomatic conditions, and preference for 
glasses versus eye medication, along with a limited amount of money to pay for 
glaucoma treatment and eye care in general. All of these contribute to the barriers to 
glaucoma treatment from the patient’s perspective. Additionally, psychological and 
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socio-cultural barriers make subsidizing glaucoma medication controversial, as it is 
argued that patients who do not pay, or pay less, for their glaucoma medication will not 
value it as much and will not use the medication, especially with the other existing 
psychological and socio-cultural barriers (Unite For Sight, 2014). 
 The last barrier to treatment was the language barrier in every direction – not only 
between the foreign volunteers and local clinic workers and patients. During outreaches 
to the Nzema region, for example, many patients spoke Nzema and not Twi, so that the 
optometrists had a difficult time giving the health talk and treating each patient. 
Additionally, patients came from Cote d’ Ivoirian refugee camps in western Ghana, and 
spoke only French.  On a particularly busy day, the outreach volunteers and workers 
would find themselves “translating in every possible direction – French to and from 
English, Twi to and from English, Nzema to and from Twi, and French to and from Twi.” 
It is certain that such language barriers would impact treatment.  
Qualitative Discussion 
 
 The information from the qualitative data was separated into the three 
components needed for successful glaucoma care – understanding of prevalence, 
obtaining a diagnosis, and obtaining treatment. For each one, barriers existed that were 
structural/economic or psychological/socio-cultural in nature, and these were further 
identified as program-side or patient-side and were different by country. See Figure 4 for 
a summary of the qualitative findings. 
 In terms of understanding prevalence, barriers were mostly program-side, 
particularly a lack of research emphasis on glaucoma by Unite For Sight. Additionally, 
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lack of population-based research studies on glaucoma prevalence by other organizations 
and entities reinforced this barrier. Such a lack of research emphasis was 
structural/economic at Unite For Sight partner clinic outreaches, in that the lack of 
recordkeeping made research on glaucoma prevalence impossible. Barriers to 
understanding prevalence were also psychological/socio-cultural from the program-side, 
as it depended on who decided and framed the important research questions. From the 
patient-side, understanding prevalence fell through when patients did not attend health 
talks or did not have eye care knowledge through other sources. The quantitative 
component of this research hopes to contribute knowledge to the understanding of 
glaucoma prevalence at UFS outreaches in Ghana.  
 In terms of obtaining a diagnosis, barriers were evenly distributed between the 
program and the patient, and were both structural/economic and psychological/socio-
cultural in nature. In terms of structural/economic barriers from the program-side, 
outreaches were poorly distributed, required payment to support the community liaisons, 
and in India, referred patients to an ophthalmologist rather than providing diagnosis 
during outreaches. In terms of psychological/socio-cultural barriers, program-side 
barriers included different emphasis on glaucoma by different clinic employees, which 
translated to an impact on diagnosis rates. In terms of structural/economic barriers from 
the patient-side which prevented diagnosis, patients had to travel far to outreaches to get 
diagnosed, had economic or other opportunity costs, and had to pay to participate at some 
outreaches. Psychological/socio-cultural patient-side barriers working against diagnosis 
included the location of outreaches in churches, other social obligations in place of the 
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outreach, preferring glasses over eye medication, and language barriers between 
staff/volunteers and patients. However, barriers to diagnosis were also ameliorated or 
reduced with the use of the health talk to educate patients (in Ghana), and the use of 
comprehensive screening methods (in Ghana) to ensure glaucoma diagnosis during 
outreach.  
 In terms of obtaining treatment, barriers were likewise distributed as either 
structural/economic or psychological/socio-cultural and at the program or patient-side. 
Program-side structural/economic barriers to treatment included infrequency of 
outreaches, differing advertisement methods depending on changing community liaisons, 
“siloing” of programs and lack of focus on glaucoma (particularly in India), and lack of 
program subsidy of glaucoma medication for the most needy. Program-side 
psychological/socio-cultural barriers included individual-level attitudes or emphasis on 
glaucoma treatment among clinic employees or volunteers. Patient-side 
structural/economic barriers to treatment included the inability to afford medication or to 
travel to an outreach for a repeat checkup; psychological/socio-cultural barriers included 
misunderstanding of the purpose of medication and emphasis on glasses, misinformed 
attitude toward asymptomatic conditions and glaucoma distribution by age, and language 
barriers between patients and clinic staff. Health talks helped reduce some of the patient-
side barriers to treatment in Ghana. 
Limitations 
 The limitations of the qualitative aspect of this research cannot be overstated. The 
source of data is purely from my own blogs and observations. No formal interviews were 
conducted, so systematic information from each location and each individual encountered 
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is not available, although I tended to ask the same types of questions everywhere given 
my general healthcare background and global health training provided by Unite For Sight 
before departure. Additionally, my blogs from Ghana were not geared towards studying 
glaucoma – I decided on this thesis after I wrote the blogs – so my research on glaucoma 
in Ghana may have been much more rigorous if I would have planned the research ahead 
of my travel abroad. Additionally, my interpretation of the situation in India was filtered 
through the lens of the experience in Ghana, and this certainly may have biased my blog/ 
observations and analysis. Even if the qualitative information was gathered more 
systematically, the information is still only based on barriers to glaucoma care witnessed 
via the work of one organization, working with a few partner clinics and with a certain 
geographic region in Ghana and India. Thus, these barriers to glaucoma care are not to be 
extrapolated to barriers to care in the entire Ghanaian or Indian population, or not even to 
patients attending non-profit outreaches. This is simply research looking at the work of 
one organization and its partner clinics and only at one snapshot in time. It is important to 
note that no single patient experienced all of the above barriers to glaucoma care. Instead, 
these barriers are a description of the potential barriers inherent to the system, and differ 
across patients and across time.  
 Additionally, the cultural limitations of being an American researcher in Ghana or 
India are huge. My ability to know what was going on around me at all times was limited 
in that I spoke neither Twi nor Tamil, and some of the information I learned was thus 
gleaned through translation or explanation. My interpretations of issues that are 
psychological or socio-cultural in nature are prone to error, and I do not have a complete 
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grasp of the healthcare systems of Ghana and India to fully be able to comprehensively 
synthesize the barriers to glaucoma care. I do not know all the inner workings of the 
partner clinics and Unite For Sight, and cannot definitively articulate the program-side 
structural and economic barriers to care. Thus, barriers to glaucoma care at each level 
may be overstated, understated, missing, or misreported due to lack of information and 
because of my interpretation as a foreigner. I hope this thesis is read with these 
limitations in mind.  
Conclusion 
 The high prevalence of glaucoma at Unite For Sight outreaches in Ghana, 
combined with the various barriers to glaucoma care in Ghana and India, illustrate that 
much work needs to be done to successfully care for glaucoma patients living in low-
resource environments. The qualitative research highlights areas of improvement for UFS 
as well as other non-profit organizations doing such work – particularly program-side 
structural changes that may improve glaucoma care. Additionally, patient-side barriers 
are important to study, as program-side changes address only one side of the barriers. The 
quantitative information shows that age and having symptoms are not related to a 
glaucoma diagnosis, so that it is important to take a comprehensive approach at screening 
all eye care patients for glaucoma. Another key lesson learned from this research is that 
location-specific analysis is very important. Extrapolating prevalence from one location 
to another is inappropriate, and attempting to reduce barriers in the same way across all 
localities may be counterproductive. Overall, understanding certain principles such as the 
need for better prevalence research and awareness, access to diagnosis, and access to 
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treatment should drive decisions for organizations doing work on glaucoma. Otherwise, 
disparities in access to eye care, particularly for lifelong, complicated conditions, will 
continue to increase. 
 The non-profit emphasis of this work shows how important the non-profit sector 
is in delivering eye care, and that this sector should be studied more to understand how 
glaucoma care can be better delivered. While this research is specific to an organization 
and future organizational research is important, additional research on this issue should 
take up the great task of better understanding the prevalence and barriers to diagnosis and 
treatment of glaucoma in all populations using other eye care delivery methods 
(governmental hospitals, the private sector, etc.). Further research on barriers to 
glaucoma care should be translated into concrete policy changes by organizations, 
communities, governments, and international institutions. Such translational research is 
crucial if attempting to truly address disparities and reduce the number of people with 
glaucoma who may otherwise become blind from the disease. 
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Appendix 
 
 
  
Number of 
Cases 
Percent of 
Sample 
25 and 
under 179 18.47% 
26-49 
years 305 31.48% 
50 and 
older 485 50.05% 
Total 969 100% 
Table 1: Age Distribution of Patient 
Population, 3 Categories 
   
  
Number of 
Cases 
Percent of 
Sample 
19 years and 
under 128 13.59% 
20-29 years 85 9.02% 
30-39 years 97 10.30% 
40-49 years 174 18.47% 
50-59 years 174 18.47% 
60-69 years 124 13.16% 
70-79 years 117 12.42% 
80 years and 
above 
43 4.56% 
Total 942 100% 
Table 2: Age Distribution of Patient 
Population, 8 Categories 
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  Male Female Sig. 
Total 43.14% 56.86%   
        
By Three Age Categories     *** 
25 and under 21.77% 15.97%   
26-49 years 33.49% 29.95%   
50 and older 44.74% 54.08%   
Total 100% 100%   
        
By Six Age Categories     * 
29 and under 24.64% 19.96%   
30-39 years 10.77% 9.44%   
40-49 years 19.86% 16.52%   
50-59 years 17.22% 18.51%   
60-69 years 12.20% 13.25%   
70 and older 15.31% 22.32%   
Total 100% 100%   
Table 3: Age & Sex Distribution of Patient Population. N=942. ***p<0.01, **p<0.05, *p<0.1. 
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  Right Eye (VAR) Left Eye (VAL) 
6\6 42.41% 38.29% 
6\9 13.31% 16.31% 
6\12 8.67% 9.59% 
6\18 5.16% 5.68% 
6\24 4.85% 4.85% 
6\36 6.40% 5.05% 
6\60 3.61% 3.10% 
CF5M 0.62% 0.10% 
CF4M 0.41% 0.93% 
CF3M 1.34% 1.14% 
CF2M 1.14% 1.03% 
CF1M 2.48% 2.79% 
Hand Motions 2.79% 4.85% 
Perceiving Light 0.41% 0.31% 
Not Perceiving Light 2.27% 1.86% 
Child 4.12% 4.02% 
Total 100% 100% 
Table 4: Visual Acuity of Patient Population. Red=legally blind. 
 
Diagnosis Percent of Sample 
Allergies 48.61% 
Glaucoma 28.17% 
Presbyopia 27.45% 
Cataract 11.25% 
Suspicious Disc 8.46% 
Refractive Error 4.33% 
Pterygium 2.99% 
Phakia 2.27% 
Immature Cataract 1.75% 
Macular Scar 1.44% 
ARMD 1.14% 
Corneal Scarring 0.83% 
Traumatic Glaucoma 0.52% 
Macular Degeneration 0.21% 
Total 139.42% 
Table 5: Prevalence of Diagnoses in Patient Population. 
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Total  
Glaucoma 
Present 
Glaucoma 
Absent 
Sig.  
    Mean Mean   
Age 
(years) 47.79 
51.10 46.50 *** 
  (21.82) (20.03) (22.37612)   
          
Age (3 categories) Percent Percent * 
  
25 and 
under 21.23% 78.77% 
  
  26-49 years 28.85% 71.15%   
  50 and older 30.31% 69.69%   
          
Age (8 categories) Percent Percent * 
  
19 years and 
under 15.62% 84.38% 
  
  20-29 years 30.59% 69.41%   
  30-39 years 27.84% 72.16%   
  40-49 years 30.46% 69.54%   
  50-59 years 27.59% 72.41%   
  60-69 years 30.65% 69.35%   
  70-79 years 30.77% 69.23%   
  
80 years and 
above 
37.21% 62.79%   
          
Table 6: Glaucoma & Age Distribution, using t-test and chi-
square. 
 N=969. ***p<0.01, **p<0.05, *p<0.1. 
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Number 
of 
Patients 
Percent 
of 
Sample 
Percent 
with 
Glaucoma 
*** 
Fetentaa 142 14.65% 20.42% 
Apampatia 100 10.32% 35.00% 
Asemase 94 9.70% 38.30% 
Asamang 93 9.60% 38.71% 
Kwanwoma 93 9.60% 15.05% 
Jini Jini 80 8.26% 35.00% 
Techimantia 72 7.43% 30.56% 
Botokrom 61 6.30% 24.59% 
Konkuli 54 5.57% 24.07% 
Wiamoase 50 5.16% 28.00% 
Derma 41 4.23% 31.71% 
Barekumaa 36 3.72% 16.67% 
Amanfrom 32 3.30% 21.88% 
Atimatim 21 2.17% 23.81% 
Table 7: Glaucoma by Village/Outreach 
Location 
 N=969. ***p<0.01, **p<0.05, *p<0.1. 
    
  
29 and 
under 
30-39 
years 
40-49 
years 
50-59 
years 
60-69 
years 
70 and 
older Total 
Village 
Glaucoma 
Prevalence 
Amanfrom 40.62% 12.50% 15.62% 9.38% 12.50% 9.38% 100% 21.88% 
Apampatia 35% 7% 20% 20% 11% 7% 100% 35% 
Asamang 12.90% 2.15% 13.98% 21.51% 21.51% 27.96% 100% 38.71% 
Asemase 26.60% 7.45% 17.02% 15.96% 14.89% 18.09% 100% 38.30% 
Atimatim 38.10% 9.52% 9.52% 19.05% 23.81% 0% 100% 23.81% 
Barekumaa 16.67% 11.11% 25% 13.89% 5.56% 27.78% 100% 16.67% 
Botokrom 11.48% 3.28% 29.51% 26.23% 6.56% 22.95% 100% 24.59% 
Derma 21.95% 19.51% 14.63% 4.88% 19.51% 19.51% 100% 31.71% 
Fetentaa 21.83% 22.54% 17.61% 19.01% 7.04% 11.97% 100% 20.42% 
Jini Jini 16.25% 10% 22.50% 22.50% 8.75% 20% 100% 35% 
Konkuli 27.78% 3.70% 11.11% 12.96% 20.37% 24.07% 100% 24.07% 
Kwanwoma 22.58% 10.75% 22.58% 15.05% 9.68% 19.35% 100% 15.05% 
Techimantia 16.67% 5.56% 13.89% 22.22% 12.5% 29.17% 100% 30.56% 
Wiamoase 12% 10% 10% 14% 20% 34% 100% 28% 
Table 8: Age Distribution by Village/Outreach; Age Dist. and Glaucoma Prevalence Bolded 
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  Right Eye *** Left Eye *** 
6\6 23.60% 26.42% 
6\9 31.01% 29.11% 
6\12 44.05% 31.18% 
6\18 30.00% 29.09% 
6\24 34.04% 29.79% 
6\36 24.59% 28.57% 
6\60 20.00% 33.33% 
CF5M 50.00% 100.00% 
CF4M 0% 33.33% 
CF3M 30.77% 36.36% 
CF2M 45.45% 1.47% 
CF1M 41.67% 18.52% 
Hand Motions 44.44% 44.68% 
Perceiving Light 50.00% 66.67% 
Not Perceiving Light 45.45% 33.33% 
Table 9: Glaucoma Prevalence at Different Acuity Levels. 
 N=969. ***p<0.01, **p<0.05, *p<0.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 95 
 
Figure 1: Approximations of Vision with Different Acuities (Trinity University 
2014)  
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Figure 2: Progression of Glaucoma (Lowcountry Eye Specialists 2014) 
 
 
 
 
 
Figure 3: Qualitative Framework 
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Figure 4: Qualitative Results Summary  
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